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Abstract
The majority of trait associated variants found in GWAS studies lie within
non coding sequences. This suggests that a large proportion of variants
alter regulatory regions. Certain genomic features has been shown useful
as marks of cell type specific activity of genomic regions. Analyzing such
genomic features against variant regions may therefore be used to find
previously unknown links between trait and cell type. Although there have
been done several investigations of this type, no easily accessible tools
for this type of research exists. This makes reproduction of such results
difficult and time consuming, hindering confirmation and updates of such
results
Such an accessible tool for studying cell-type specificity of genomic
regions is presented here, created in a Galaxy-based web interface at the
Genomic HyperBrowser server. It allows the user to run a selection of
analyses on their own genomic variation data against genomic tracks of cell-
type specific marks. A table presenting the main results provides a broad
overview of themost relevant cell types, while links to further details behind
each main result allows for deeper investigations.
The tool here presented allows anyone to run such analyses without
deep knowledge of statistics and informatics, as most parameters and
variables are set automatically by the system. Combined with the graphical
interface in the HyperBrowser, this makes it easy to specify and reproduce
analyses.
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Chapter 1
Introduction
Deoxyribonucleic acid (DNA) can be seen as the blueprint of life. It is DNA,
together with environmental factors, that designs you as human, and just
as most humans are similar, so is the DNA between humans much the
same. But there are differences. Some of these differences are more or
less harmless, eye color, hair color and skin color are all traits that to some
extent are determined by the DNA [27]. Cancer, Multiple Sclerosis and
Alzheimer are traits with more serious consequences that also have been
linked to variations in the DNA [14][13][40]. Genome-wide association
study (GWAS) are among the techniques used to connect genetic variations
to traits.
There have been much work done within the field of GWAS, and more
and more genetic markers for diseases and traits are being mapped and
collected. In 2010 more than 50% of the papers published in Nature
Genetics was GWAS related [22]. Publicly available databases contain
huge amounts of information, about markers for cell types, and markers
for traits and diseases. Much work is carried out with this data, but a lot
of the work is done on custom-made computer software or on a selection
of different tools[5]. This can make it time consuming and difficult to
reproduce results.
Creating a custom made computer software for analysing genetic data,
including GWAS data, can be very time consuming, especially if including
the time it takes to assure correctness and improving readability. Time
that otherwise could have been spent doing research, is used to create
the tools needed for the research. By creating a publicly available tool
with a graphical interface that is easy to use, it might be possible for
the scientists to save time by being allowed to focus on research and not
software development.
1.1 Genomic variation analysis tool
The basic idea is to create a tool that allows the scientists to do statistical
analyses on genomic data against given genetic regions, without having to
worry about all the statistical variables. It is to do statistical analyses and
comparison on genetic data for a trait against user chosen genetic regions.
3
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The results should be presented so that it is easy to see which of the analyses
that gave interesting results, and where it could be interesting to take a
closer look at the data.
The goal is that it must be easy for the user to choose what to run the
analyses on. They should have access to pre-stored trait data, but also
be allowed to upload their own research data. They should be allowed
to choose between a few but relevant genetic regions to run their data
against, and they should be allowed to choose more than one region. These
genetic regions will contain subtypes, these subtypes are the phenotyped
regions. One example of this is the chromatin state active promoter as
genetic region, and b-cells as one of the subtypes.
The user should have a few but relevant analyses to choose from, also
here it should be possible to select more than one. Relevant analyses will
tell if there are any relations between the genetic data.
The tool will be implemented in the Galaxy-based Genomic Hyper-
Browser, which gives a web-based graphical user interface and tools for
publishing and reproducing results.
1.1.1 Flexibility
The goal is to make the tool flexible, but still easy to use. It should let the
user do some selections, but is should not bog down the user with too many
choices. The tool should only show the necessary selections at all times.
This way the user only has to focus on what is needed for that specific run,
while still being allowed some individual selection. The main focus will be
on ease of use.
1.1.2 Presenting the results
When all analyses are done, the results should be presented in a way that
makes it easy for the user to get an overview of the results. Since the
user should be allowed to run several analyses on several genetic regions,
it can not present all information up front. Some information must be
selected, and presented as the main result. This information will have to
be representative for the local results for that subtype. Graphs should also
be presented for at least some of the analyses.
1.1.3 Checking the result
The final step for this tool will be to do some analyses on genetic variations
for MS, and then confirm the relations between MS and B cells, as found
in “Genomic Regions Associated with Multiple Sclerosis Are Active in B
Cells” [13]
1.2 Genomic track overlap algorithm
In the HyperBrowser there are various algorithmic implementations to
compute the number of base pairs overlapping between two genomic
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tracks, depending on properties of the tracks and how the data is
represented. The analyses involved in this project relied heavily on the
computation of overlap between genomic tracks, where there could be
intra-track overlap between segments of one of the two tracks.
As existing algorithms for this situation were either slow or had
particular requirements on how the data were represented, it was decided
to develop an improved algorithm for computing base pair overlap between
two tracks, where one can have intra overlapping segments.
1.3 Accessibility
The tool, Analyze TF- or cell type-specificity of a genomic track, is publicly
available at http://hyperbrowser.uio.no/personal/, under the Restricted and
experimental tools link. It is publicly available for anyone interested, with
some histories available under Shared Data and Published Pages.
A copy of all the files can be found at http://hyperbrowser.uio.no/dev2/
static/downloads/kriswalo-files.tar.gz.
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Background
This chapter will go through useful background information. It will cover
fields such as genetics, which is the field bioinformatics is working on. Then
bioinformatics will be explained, bioinformatics is one of the fields that
work with data collected from Genome-wide association study (GWAS).
Then it will be taken a closer look at personal medicine, which might be
said to be one of the fields benefiting from the work done in GWAS and
bioinformatics. Then the focus will shift to the more technical aspects. It
will be taken a closer look at the programming language python, which
is the language the Genomic HyperBrowser is written in. The Genomic
HyperBrowser is the framework the tool is built within, and will be
described in the section after Python. The final technical aspect that is
covered in this chapter is legacy code, as the HyperBrowser is a good
example of legacy code. The last section of this chapter will go through a
set of articles containing important information that has been used in this
work.
2.1 Genetics
DNA and RNA are known as nucleic acids, and DNA contains four
nucleotides. Nucleotides are the building blocks of both DNA and RNA [6],
and when the nucleotides are linked together in a linear manner they
form a strand [6]. Two strands can be bound together to create a double
helix [6]. When DNA is associated with proteins into a compact structure
it is called chromatin, while if it is an array of different proteins it forms
chromosomes [6]. One nucleotide contains only one of five possible bases:
adenine (A), guanine (G), cytosine (C), thymine (T) and uracil (U), where
thymine is unique for DNA, and uracil for RNA [6]. The AT/CG rule says
that if you know the sequence of one strand, you also know the sequence
of the opposite strand. For example, if one strand is GCGGATT, then the
opposite strand has to be CGCCTAA [6].
DNA replication is a process in living cells, a process that needs
speed, accuracy and that must avoid leaving gaps in the newly made
strands [6]. It is very accurate, with less than one mistake for every 109
base pair copied [30]. But when such a permanent error occurs, it called a
7
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mutation [6].
A gene is a linear sequence of amino acids that encodes a polypeptide,
where polypeptide means structure [6]. A protein, on the other hand,
means function, and a protein can be created from one or more genes [6].
The process from gene to polypeptide contain several steps, but can
be roughly summarized in two, transcription and translation. The
transcription creates a RNA copy of a gene, more specifically messenger
RNA (mRNA) [6]. The mRNA is then transported to the ribosome, which
then translates the mRNA into a amino acid sequence of a polypeptide [6].
Two other types of RNA are transfer RNA (tRNA), which translates the
mRNA, and ribosomal RNA (rRNA), which forms a part of ribosomes [6].
This means that for some genes the RNA is the product in itself [6].
Ribosomes are composed of many proteins and rRNA, and provides
a location where mRNA and tRNA can interact [6]. Generally the
transcription starts near a site in the DNA called the promoter, and
the terminator signals the end of the transcription, while the regulatory
sequence either increase or inhibit the rate of transcription [6].
Normally DNA is tangled together around histones (proteins), but
usually there are strains of DNA less tangled together. These strains
are usually genes more sustainable to transcription and are called DNase
hypersensitive sites (DHS). DNase is enzymes that digest DNA[6]. These
sites may have different positions depending on what cell type the gene is
working within.
A mutation in a coding sequence may not affect the function of the
polypeptide or protein, it is then called a neutral mutation [6]. While
a nonsense mutation is a mutation that makes the translation end to
early, this often leads to polypeptides not functioning as normal [6]. A
frameshift mutation adds or deletes nucleotides that are not in multiple of
three, this shifts the reading frame so that a completely different amino
sequence occurs. This is likely to inhibit the protein function [6]. A
mutation may also occur in noncoding sequences, and in that way increase
or decrease the rate of transcription [6]. Proteins that control the ability to
transcribe genes is called transcription factors (TF), hence the position will
be cell specific [6]. H3K4me3 is a protein working as promoter for active
transcription sites [31].
Phenotype is how the genes get expressed [6].
2.2 Bioinformatics
Bioinformatics is the systematic analysis of information relating to biolog-
ical macromolecules with the aid of computers [42]. Macromolecules are
large molecules such as nucleic acids, lipids, proteins and carbohydrates.
The early fundamentals of bioinformatics can be traced all the way back to
the 1960s, but the term bioinformatics did not exist at that time [42]. In
the 1980s the GeneBank was established, which is a database for collect-
ing all publicly available DNA sequences. And with it came algorithms for
fast searching in databases, such as FASTA and BLAST [42]. But the main
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reason bioinformatics gained popularity was the advancement of genome
studies that now produces huge amounts of biological data [42].
Bioinformatics is a term used for the research field where biology meets
computer science [42]. Many definitions exists, the term can be used for
research that uses computers for storage, retrieval, manipulation, and dis-
tribution of information related to biological macromolecules [42]. The
broader term computational biology also includes biological areas that in-
cludes computations, such as mathematical modelling of ecosystems, pop-
ulation dynamics and application of game theory in behavioral studies [42].
But there does exist other definitions as well, and hence these should not
be seen upon as the only correct definitions.
One could say that the ultimate goal in bioinformatics is to better
understand the living and how it works at the molecular level [42].
Bioinformatics can help us understand this by analysing and simulating
how DNA becomes proteins [42].
The development of computational tools, and the applications of these
tools to get a better understanding, can be said to be two subfields of
bioinformatics[42]. These two fields are very much dependent on each
other, you need the tools created to study the genomic data we have. As
we learn more, new questions arise, and new tools are needed.
It is important to recognize the limitations of bioinformatics. The
results are not formal proof of concepts, and they do not replace traditional
research [42]. There are many places an error may arrive, and start to
snowball. Bioinformatics is no better than the data it is based upon, and
sequence data often contain errors [42]. It is also important to remember
that bioinformatics often works with huge amounts of data, which means
that the algorithms have to make a choice between accuracy and speed,
while at the same time algorithms lack the capability to completely and
truthfully reflect real life [42]. Hence it is important to run research
on several types of data if available and with several different types of
algorithms to find a consensus by comparing all the results [42].
2.3 GWAS
2.3.1 GWAS introduction
GWAS is short for genome-wide association study and is the search for ge-
netic variants across the human genome in an effort to identify genetic risk
factors for diseases that are common in the population [7]. Genetic variants
can be in the form of SNPs, or less common mutations. These genetic vari-
ants can then be used formany applications in research and clinical practice
of medicine, such as preventive medicine, personalized medicine, pharma-
cogenomics and pharmacogenetics. One of themost successful fields within
GWAS has been pharmacology [7]. In pharmacogenetics the goal is to iden-
tify DNA sequence variations that are associated with drug metabolism and
efficiency as well as adverse effects [7]. One example is warfarin (see sec-
tion 2.4.2).
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A genetic variation in a single allele that occurs with a high frequency
in the population is called a single nucleotide polymorphism or SNP [7].
SNPs are typically used as genomic markers for a genomic region, with
the large majority of them having minimal impact on biological systems.
SNPs can have different functional consequences such as causing amino
acid changes, changes to mRNA transcript stability and changes to
transcription factor binding structure (that suggests common origin) [7].
Within a population a SNP typically has two commonly occurring base-
pair possibilities for a certain positions. The frequency of a SNP is given
by the frequency of the less frequent allele [7]. This means that if a SNP
with the minor allele (G) has a frequency of 0.3, that implies that 30%
of the population has this G allele, compared to the more common allele,
which then is found in 70% of the population. Very rare diseases can be
caused by genetic variants with very low frequency, and the genetic variants
is then often referred to as a mutations, although they can be structurally
equivalent to SNPs [7]. In genetic literature the term SNP is generally
used to common single base-pair changes, and mutation to rare genetic
variants. If a SNP has 30% frequency in the population, and almost directly
leads to a disease phenotype, almost 30% of the population would have
that disease [7]. Then the allele frequency and the spread in the population
would be almost correlated. But if the SNP causes a small change in gene
expression that just changes the risk for a disease by a small amount, the
prevalence of the disease and the allele frequency would only be slightly
correlated. Hence common variants almost by definition cannot have high
penetrance [7]. It has been found that around 40% of trait-associated SNPs
fall in intergenic regions, and another 40% are in noncoding introns [28].
These results have made the role of intronic, and particularly intergenic,
regions to gene expression interesting. Another interesting result from
GWAS is the finding of SNPs related to a disease in genes earlier not
believed to have any connection to that certain disease [28].
When embarking upon a genetic study, the initial focus should be on
identifying precisely what quantity or trait the genetic variations influences.
The most common design for GWAS is the case control design. In the
case control design the allele frequency in patients with a certain trait is
compared to patients without the trait. This design is often easier and less
expensive than studies using other designs [33]. This design also carries the
most assumptions, and if mistaken, can lead to severe biases and wrongly
made associations [33]. One of the most important biases is that of the
unrepresented case participants. These participants are typically gathered
from clinical sources and therefore may not include fatal, mild or silent
cases not coming to clinical attention [33]. It may also be difficult to ensure
the comparability of the case and control participants, who may differ in
important ways that could effect the genetic risk factors [33].
2.3.2 History
In 2000 a collaborating project was started up, the project’s mission was
to identify up to 150 000 SNPs throughout the human genome within two
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years, and to make the information available to the public [22]. In April
2003 the sequencing of the human genome was announced completed.
99% of the gene-containing part of the human sequence was finished
with 99.9% accuracy. But the human genome sequence has still not been
finished, there are still many gaps in the reference sequence. And given
the variation of the human genome, one might always ask what is the
completion of the human genome [22]. The idea behind the HapMap
project was to create a public genome-wide database of common human
sequence variations, providing information needed as a guide to studies of
clinical phenotypes. The researchers created a database of 1 million genetic
variations for 4 representative populations, Africans, European Caucasian,
Chinese and Japanese [22].
This made GWAS easy to do, just collect DNA from patients, genotype
it, and then do some statistical analyses on the results. Genotyping became
work, not research, and commercial genotyping systems have spread all
over the world. By sharing control groups, collecting them is no longer nec-
essary, except for diseases with extraordinary high prevalence(>10%) [22].
As a consequence of HapMap, commercial genotyping systems, such as Il-
lumina, have spread out around the world, and with them, GWAS as well.
In 2007 the study of genetic polymorphisms (SNPs) and its applications
were selected for the No. 1 scientific event of the year [22]. And as men-
tioned previously, 56% of 181 published papers in Nature Genetics was
GWAS related [22]. Some of the diseases that have been linked to genes
are obesity, hypertension, diabetes and osteoporosis [22].
2.3.3 Common problems
A frequent complaint against GWAS is that the results mean little to
patients due to the small effect of variants on disease risk [22]. For
example, one paper reported that a certain SNP was associated with height,
but its estimated additive effect is only 0.44 cm on height [37]. Another
example is a GWAS study that found that a certain allele is related to the
cartilage thickness of the hip joint measured on X-ray films. Those with
the allele had a 0.07 mm narrower joint [8]. This shows that GWAS is
not a conclusive method, it is a method to map the gene; an associated
variant is not necessarily a true casual variant [22]. Another problem comes
from the controls with ambiguous definitions of populations, such as "UK
Caucasians" or "Western Europeans". This results in a compromised result
by adding a mixture of different ethnical subgroups. Hence it is important
to detect population layering prior to analysis [22]. It is important that
statistics leads to biology, and biology to medicine. There are still many
more genes to be identified. The gene DVWA, which has been associated
with osteoarthritis, and was found in what was thought to be a gene desert
region when found in 2004 [22]. There is also a big chance of error in the
grouping of individuals "case" or "control". Take for example the disease
multiple sclerosis which is a complex disease often diagnosed over a long
period of time by ruling out other possible conditions, here individuals
could easily end up in the wrong group. Despite this loose classification
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of case and control, GWAS on multiple sclerosis have been very successful,
implicating more than 10 new genes for the disorder [7]. To predict the
chance of getting a complex disease, genotypes at multiple SNPs are often
combined into scores calculated according to the numbers of risk alleles
carried. From what is seen so far it is obvious that genetically based
risk assesment of disease occurrence is too uncertain to be of any clinical
predictive value. But that might change as the sample size increase and
more risk variants are identified [28]. A huge challenge for the physicians
and patients in years past and years to come is correct communication
of risk prediction, because the perception of risk is often more heavily
influenced by emotion than science [28].
Another problem within GWAS is the false positives [22]. With P < 10−3
we have 1 in 1000 coincidence. Or if you try 1000 times, you can hit 1 target
and 100 000 times, 100 targets by chance. Consequently it is important
with replication of studies, but not on the same population, as it may
duplicate the same errors as in the previous study [22]. For this reason
replication in large samples are the best way to duplicate associations [22].
GWAS can easily be seen upon as a way of identifying markers for
genetic identifiers and risk assesment. By knowing the genetic risk we can
take steps towards minimizing other risk factors through our way of life.
Also by studying the meaning of allelic difference of causal variants, it is
possible to clarify the molecular development of the disease. And with that
knowledge create innovative treatments and discover new drugs [22].
2.4 Personalized medicine
2.4.1 Introduction
As mentioned in section 2.3 both personalized medicine and avoiding
adverse drug effects can be among the goals of GWAS. And both of these can
be put under the category personal medicine. Personal medicine is a wide
ranging subject with many topics. To define it in one sentence is difficult.
And there is no general consensus on what personal medicine is, only that it
is the future [26]. It is not a question about if, but when. Personal medicine
may be considered as finding the most efficient treatment based on genetic
variations. Or it may be used to increase drug safety, by maximizing the
health benefit andminimizing the chance of adverse drug effects. But this is
not the only topics under personal medicine. Personal medicine can also be
seen as preventing, diagnosing, treating and optimizing individual health-
care decisions [26].
2.4.2 Current status
One field within personal medicine focuses on finding molecular biomark-
ers for drugs. This is usually done post hoc, by looking at the data after the
trials for a new drug have been concluded. Three examples that used post
hoc analysis are: abacavir, used against HIV and Aids; irinotecan, used
against cancer; and warfarin, used against thrombosis (information can be
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found at www.drugbank.ca). It can be argued that it is better to co-develop
drugs and tests for biomarkers, as have been done with trastuzumab, used
against breast cancer. They created a diagnostic tool concurrently with the
drug, and got it approved and recommended by the FDA. FDA is the Food
and Drug Administration in the US, they have to approve the drugs before
they can hit the US market. Similar administrations exists in most coun-
tries and the EU. Creating the diagnostic tools concurrent with the drug
might help targeting user groups that the drug has the desired effect on.
The tool can then be presented to the FDA as a selection criterion, and
hence increasing the chances of approval. The diagnostic tool can also be
used to remove selected groups with increased possibility of adverse drug
effects. Hence also increasing the chances of approval, while decreasing the
chance of ending up like Rofecoxib. Rofecoxib was originally approved in
1999 as a drug against inflammations, but it was discovered to drastically
increase the chance of heart attack, and thus removed from the market in
2004. Sponsors of drug development seem to think that it is common to
co-develop diagnostic tools and drugs, but in reality co-development rarely
happens due to uncertainty about the economical benefit [10].
Currently there is a productivity problem in the pharmaceutical indus-
try [26]. Although the research and development has increased drastically,
there has not been an increase in approved drugs. There are many theories
as to why this is the case, but one thing is clear, the old business model is
at least partly responsible. The pharmaceutical companies have been look-
ing for groundbreaking drugs, drugs that fit everyone and work well. These
drugs have high development cost, but have so far paid for them self by hit-
ting a big need in the market and hence selling huge amounts. Rofecoxib
was one such drug, selling for more than $2.5 billion per year until was
withdrawn due to side effects [26]. As more and more of these drugs have
been discovered, it’s gotten harder and harder to find new ones. And the
question now asked is, can this business model be maintained? There seem
to be a change within the pharmaceutical industry towards drugs that works
well on some, and to find that group they want to use genomic biomark-
ers. This will increase the capital to a section of personal medicine, and
might very well be something that very well speed the arrival of personal
medicine.
2.4.3 Genetics directly to consumer
As mentioned in section 2.3.3, one of the problems physicians face is to
correctly communicate risk assessments. The companies within genetics
directly to consumers, are trying to sell this type of information to
consumers.
So far more than 100 000 individuals have tested their DNA against
the more than 1000 DNA variants associated with diseases [23][32]. The
direct-to-consumer, DTC, industry sends the consumer a small package
for sampling the DNA, and within a few weeks, they present the absolute
risk for certain diseases. Absolute risk is calculated from relative risk
and average population risk, where relative risk is based on the individual
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genetics, while average population risk is based on the population. The
average population risk variable will change depending on how you define
population and hence there may be some deviation between the different
companies. But even in relative risk there are differences to be found. In
[32] they sampled the DNA of five persons, 3 females and 2 males, and sent
them to Navigenics and 23andMe to test against 13 diseases. They found
that the two companies on some of the diseases had different population
risk and relative risk. This despite that the companies agreed on more than
99.7% of the DNA bases observed [32]. So why do they not agree on risk
predictions? For one, Navigenics separates between men and women on
population risk, while 23andMe uses age. Another reason is that they do
not use the same set of markers when it comes to calculate relative risk, and
because of that the results will vary [32]. This implies that the companies
will not always agree on the absolute risk of a certain disease. It was shown
that for 7 diseases they found that 50% or less of the predictions agreed
across the five individuals [32]. On Crohn’s disease the two companies
varied from high risk to low risk on two of the five candidates, and between
average and low on the third. This highlights what was mentioned in
section 2.3.3 that GWAS has had very little impact on patients and that
there is still some uncertainty about the direct use of it, although some
companies are already selling products using this information.
2.5 Python, the language of choice
It is practical to divide different programming languages into two cate-
gories: typesafe languages and dynamically typed languages. Typesafe lan-
guages bind variables to certain data types, while dynamically allows vari-
ables to hold any type of data [25]. Another typical way of classifying the
languages is by defining them as high level or low level languages. High
and low does not represent quality, but how they are written. High level
languages are close to natural language specifications of algorithms, while
low level languages are closer to hardware level. Python and Perl are ex-
amples of high level languages, while C and Fortran are low level. C++ and
Java would then end up somewhere in between [25]. It is worth noting that
there are no strict borders between high and low level languages. There is
also a question about how low the high level languages go, and how high
the low level languages go.
There are mainly two reasons for Python’s success in scientific comput-
ing. First of all, Python typically gives readable and concise code, which
in return makes for faster development cycles. Secondly there is Python’s
access to its internals from C via the Python/C API [4]. Python’s role in sci-
entific computing is usually binding together existing components instead
of reinventing the wheel. For example, SciPy, a Python specific package,
contain more than 200 000 lines of C++, 60 000 lines of C, and 75 000
lines of Fortran, compared to about 70 000 lines of Python code [4].
14
2.6. THE FRAMEWORK
1 F = open(filename, ' r ' )
2 n = F .read( ) .split( )
Listing 2.1: Reading elements from a file into a list in Python.
2.5.1 Efficiency
The high level and flexibility of Python will necessarily imply some loss of
efficiency, especially when traversing big data structures. However, with
modern computers, it may often be fast enough. A factor of 10 times slower
code might not really matter when the statements in the script is executed
in a few seconds or less [25]. In some cases the high level language will
give near optimal efficiency. An example of that may be the need to read
numbers from a file. The file may contain an unknown amount lines,
and each line an unknown amount of numbers separated by an unknown
amount of whitespace or tabs. This may in some languages be a task
demanding many lines of code. In Python it takes only two (example from
“Python Scripting for Computational Science”[25]).
The code snippet in listing 2.1 solves the problem for us, and does it
by calling highly optimized C code [25]. This code has been optimized
by many people around the world, and it follows that it will be hard to
beat the speed of the Python implementation [25]. This means that in the
area of text processing, dynamically typed languages such as Python can be
very efficient from both human and computer point of view [25]. Another
benefit of Python is that it has very good options for moving CPU heavy
operations into C, C++ or Fortran. This means that heavy computations
on big arrays of numbers can be done in a faster language such C, while
Python sets up all the needed variables and binds these number crunching
loops together. Cython is one such tool, and will be discussed a bit more in
section 4.2.3.
2.6 The framework
As with any new type of field of science, the research within genomic
analysis is done with several techniques and assumptions. That makes
it difficult to compare, reproduce and realize the full implications of
various findings. The Hyperbrowser is a tool for analysing sequence-
level genomic information built upon the Galaxy framework. Some of the
more prominant tools are Galaxy, BioMart, EpiGRAPH and UCSC Cancer
Genomics Browser. Biomart offers flexible export of user-defined tracks
and regions. Galaxy offers a richer, text-centric suite and operations.
EpiGraph has a solid set of statistical routines focused on analysis of
user-defined case-control regions. While UCSC Cancer Genomics Browser
visualizes clinical omics data, as well as providing patient centric statistical
analyses [36]. Omics data are fields in biology ending in -omics, such as
genomics and metabolomics.
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2.6.1 Galaxy
Thanks to new sequence technology, there exists a vast amount of
sequenced genomic data, but for most biologist, there is a void between
accessing all this data and translating it into biological knowledge. The
main problem might be the immense size of the genomic data sets [5].
Another problem is the incompatibility between formats. This is often
solved by small custom one-off scripts, and while these scripts might be
simple, they are a real problem to reproducibility if not made publicly
available. If the scripts are made available, they often have confusing or
command line only interface [5]. Rarely does the output of one tool work
directly with another tool. This means it is practical for for biologists
to have tool to use on hetrogenous data sources; Galaxy offers datatype
converters for such data sources.
2.6.2 Hyperbrowser
The Hyperbrowser is a tool for comparative analysis of sequence-level
genomic data by mixing genomics, computational science and statistics.
It is based on an abstract representation of generic genomic elements as
mathematical objects. Where hypotheses of interest are translated into
mathematical relations. By using mathematical models, one can create
randomized tracks with track structure preservation to build problem-
specific null models about relations between tracks [36]. Some analyses
of potential interest for two tracks, T1 and T2, may be: are the T1 points
overlapping more with T2 than expected by chance, does the midpoints
of on track overlap more than expected [36]? Information reduction of a
track, from segments to points, may open for several new analyses, and this
is handled dynamically within the system. analyses may be done globally
or locally. A global analysis is an investigation of certain relation between
two tracks as a whole, while local analysis is based on dividing the tracks
into smaller units, called bins, and then performing the analysis on each
bin separately [36]. Local analyses may be of interest to check if there
may be any relation between certain biological mechanisms [36]. The local
analyses can be used to see where there are any relations between a trait
track and different cell types.
The Genomic HyperBrowser is open source and based on the Galaxy
code. It is implemented in Python. One of the weaknesses of pure Python is
slow runtime, see section 2.5.1. Therefore the HyperBrowser is built in two
layers. On top it is created by Python for flexibility, and at the lower level all
the tracks are stored as low-level vectors, numpy.ndarray [36]. This gives
efficient storage, and allows the use of highly efficient numpy operations to
ensure speed [36]. The system uses a web-based interface with an easy-to-
use entry point. However, all the different analyses and how they interact
with different tracks, and all the different null models, can make it difficult
to get an overview and not so easy to use. To help with this a step-by-
step approach has been used so that only the relevant and possible options
are available at each stage. When something is selected, the HyperBrowser
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tries to do short runs on all the implemented analyses, using a small part of
the selected data, if the analysis fails, it is removed from the list of possible
analyses [36].
2.6.3 Batch line commands
The HyperBrowser has the option to run batchline commands. That is a
way of automatically running many tests on many tracks with just a few
lines of code. This also makes for easier reproduction of results, as the
batchline commands can be included in any report and rerun to do identical
tests again. Variables can be defined as constants, or dynamically, so that
is changes for each run.
1 @TNbins=<Path to disease>
2 @TN2s=Private:GK:Psych:DHSs: *
3 @binning=track|@TNbins
4 hg19|@binning|@TN2s| |NumBinsContainingElementsStat(tf1=←-
TrivialFormatConverter)
Listing 2.2: Example of batch lines
Listing 2.2 is an example of how a run could be written with batchlines.
The @ is used to define variables, such as the trait track, and what tracks
that trait is to be compared against. In this example, the variable @TN2s
will represent all subtypes of DHS. Such as A549, CD19 and HAEpiC. The
final line represents the actual command run. A list of processed command
lines will be generated, such that the variables have been swapped with
what they represent. In this, case that means it would be a list of batchlines,
where there is one batchline for each subtype of DHS. The * is what tells the
HyperBrowser that there may be more than one subtype to use.
2.7 Legacy Code
A definition of legacy code may be code gotten from someone else. It is
someone else’s code [16]. Some may associate legacy code with tangled
unintelligible structure, code that you have to work with but do not fully
understand [16]. In industry it is often associated with difficult-to-change
code, code that is hard to fully understand [16].
There are mainly 4 reasons to change legacy code, adding a feature,
fixing a bug, improving design or optimizing resource usage [16]. Adding
a feature may include many things, it may be changing something while
adding, it might even be removing something to add something else.
Or it may be to add something completely new outside the old code.
The HyperBrowser may be seen upon as legacy code, it is not very well
documented and it seems like every part of it is dependent on some other
part. There are mainly two ways to change something in a system of legacy
code, one is the Edit and Pray and the other is Cover and Modify [16].
Edit and Pray is more or less the standard in industry [16]. With Edit and
Pray, it is usual to build up an understanding of the code, then plan the
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changes, then carefully make the changes. When the changes are done, the
system is run to sees if it works. If it does, the next step is to prod around
looking for mistakes, and to check if it all works as it should. The prodding
is really important as it is done to make sure that nothing broke during the
implementation. Cover and Modify uses a slightly different approach. In
this method it is usual to cover the code with tests before any changes. That
way the test will immediately fail if the changes break any dependencies
or any input or output changes. By covering the code with tests before the
change it is very easy to see what the changes result in, and if it has any
unintended side effects.
2.7.1 Unit testing
The definition varies, but it refers to testing the smallest components in the
code. In procedural (similar to functional programming) code it is usually
methods or functions, while in object-oriented code it is usually classes
or objects [16]. Testing these parts in isolation can be difficult, because
functions usually use functions that use functions, and classes are usually
dependent on other classes. The isolation part is very important. If the test
is large, some problems arise, such as where is the problem located, and
it takes too long time and how to make sure all possibilities are covered.
These problems are easier solved in unit tests than in higher level testing.
Unit tests make it possible to run pieces of code independently, or they can
be grouped together and run under the same conditions. Unit tests also
make it easy to localize problems. Two qualities of good unit tests are that
they run fast and they help localizing problems [16].
A unit test that takes more than 1/10th of a second is slow. Unit tests
are supposed to be small and local. If you start to group the unit tests
together, it takes much longer. Say you have 1000 methods, and about 10
tests for each. That would make it 10000 tests, and if each test take 1/10th
of a second, that makes it 1000 seconds, or 16 minutes. That is not fast
enough for unit tests, the feedback should be almost instant. Otherwise it
is very easy to find excuses not to run the tests. If a test uses a database,
communicates across a network, touches a file system or need to change
anything in the environment (like configuration files), it should not be
considered a unit test [16].
It is usual to have to change some code to be able to add tests to untested
legacy code. And that gives rise to The Legacy Code Dilemma as stated in
“Working Effectively with Legacy Code” [16].
When we change code, we should have tests in place. To put
tests in place, we often have to change code.
One way to work around this dilemma is to use the legacy code change
algorithm [16]. Firstly one find the change points, the points where the
code needs to be changed. When these points are found, one can find the
possible test points around that. Then one breaks the dependencies and
write tests. Then all left is to make the changes and refactor the code [16].
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2.7.2 Adding a feature
One of the most powerful ways of adding a feature to any code is the use of
test-driven development (tdd) [16]. The idea is to write a test that will fail
in the beginning, then you develop the code to make it pass. The benefit
from this is that you need to clarify the input and output of the method
before any code is written. The steps for tdd are as described in “Working
effectively with Legacy Code”[16]:
1. Write a failing test case
2. Get it to compile
3. Make it pass
4. Remove duplication
5. Repeat
Following is an example of creating a division method in Python. This
method will be divide10byX(x), and it will divide 10 by the user given x.
Writing a failing test case
The fist thing to do is to create a test that calls the method to be added,
with values such that it is easy to control the result. This test case will
immediately fail since the method is not yet created. For the same reason,
this code would not have compiled if it was a compiling language.
1 def testDivide10byX( )
2 res = divide10byX(2)
3 assert(res==5)
Listing 2.3: Legacy Code: Failing test case
Get it to compile
If this was a compiling language, the next step would have been to make it
compile. That is done by creating the wanted method, but make it return
something useless. Say for example the boolean False. This would make
the code compile, but since this is Python is only changes the errormessage.
The assertion would still fail when running the code, this due to the method
not returning what is expected.
1 def divide10byX(x) :
2 return False
Listing 2.4: Legacy Code: Making it compile
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Make it pass
Next up is to make the test pass. This is done by making the method do as
originally planned. In this case it is a matter of returning 10 divided by x.
Now the test will tell if the method is implemented correct so far.
1 def divide10byX(x) :
2 return 10 ./x
Listing 2.5: Legacy Code: Make it pass
Remove duplication
In this part of the algorithm one try to factor out parts of the code that do
the same, and whenever that is found, factor it out into another method.
This is done to make the code easier to maintain and read. In this example
there is no duplication, but an example could be if another method existed,
that divides 20 by x. Then it might be natural to create a method that can
divide any number with any number, and thenmake the other twomethods
call that one, where one sends in 20 and x, and the other sends in 10 and x.
Start over
The final step step is to start over again, find possible points of errors and
make tests for them. Possible errors for this example are integer division,
and division by zero. By adding tests for possible errors, it is shown that
these cases are accounted for and tested. It also helps others understand
the code, and makes it easier to avoid breaking dependencies.
2.8 Essential articles
Here follows some summaries of some articles that are important for
the design of this thesis. They have been important in selecting what
genetic regions to include and also what type of analyses to include.
Many of the technical terms used are explained in table 2.1. The articles
summarized are “Genomic Regions Associated with Multiple Sclerosis Are
Active in B Cells” [13], “An integrated encyclopedia of DNA elements in
the human genome” [15], “Systematic Localization of Common Disease-
Associated Variation in Regulatory DNA” [29], “Chromatin marks identify
critical cell types for fine mapping complex trait variants” [39], “Predicting
Cell Types and Genetic Variations Contributing to Disease by Combining
GWAS and Epigenetic Data” cite[18] and “Next-generation sequencing
in understanding complex neurological disease” [20]. Unless otherwise
stated, all the facts in the summary will be from the article summarized.
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Cell type Explanation
B cells A type of white blood cells [3]
Hepatocytes A certain type of liver cell [34]
Fibroblasts A cell found in connective tissue [17]
Keratinocytes Cell in outer layer of skin [24]
CD-20 A protein primarily in the surface of B cells [38]
Rituximab An anti-CD20 monoclonal antibody,
destroying B cells [13]
Linkage disequilibrium A non random association [21]
de novo Latin: From the beginning [12]
Rheumatoid arthritis Chronic inflammation of the joints [35]
LDL Low-density lipoprotein, generally referred to
as bad cholesterol [9]
cDNA Complementary DNAmade from mRNA [11]
GWAS integrator Tool allowing cross database search [43]
HaploReg Tool for exploring annotations on the
non-coding genome [41]
Table 2.1: Explanations of terms and names used in essential articles
2.8.1 Genomic Regions AssociatedwithMultiple Sclerosis
Are Active in B Cells
So far, more than 50 genomic regions have been shown to influence the risk
of multiple sclerosis (MS), but it is still largely unknown in which cell types
these variants acts. Hence, it is hypothesized that these regions would co-
localize with regions known to be active in B cells, due to the role B cells
have been found to have in MS.
Background
Multiple sclerosis (MS) is a disorder affected by both genetic and environ-
mental factors, and it damages the central nervous system. In one research
they found evidence of 57 genomic regions being associated with MS, but
the knowledge of how those regions are involved in MS development is
limited. Rituximab’s (explained in table 2.1) success in treating MS have
heightened the interest in B cells’ role in MS, and now other anti-CD20
monoclonal antibodies are undergoing clinical tries.
Many of the SNPs associated with MS do not lie in coding regions of the
DNA, which makes it likely that they affect the disease risk through a gene
regulatory role. The lack of distinguishing sequence signature makes those
regulatory elements in the genome much harder to identify than protein-
coding genes, although this does not mean they are less important. To find
these regions, one can use chromatin profiling, which is a powerful tool to
detect regulatory activity. The chromatin region of a cell does among other
roles, determine which regions of the genome are accessible to the binding
transcription factors and whether transcription occurs or is repressed. It is
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also distinctive for a certain cell type. A study has mapped the chromatin
marks of nine different cell types to characterize regulatory elements and
their cell type specificities. Among the cell types were B cells, hepatocytes,
fibroblasts and keratinocytes. See table 2.1 for explanations. Since many
of the SNPs associated with MS might influence disease risk through a
gene regulatory role, it is plausible that these SNPs should be observed
with a higher rate in the regulatory regions for the cell types causing or
affectingMS. Hence, they hypothesize that they should find a bigger overlap
between MS SNPs in the regulatory regions in B cells compared to non-
immunological cell types.
Methods
The genetic variants for MS were collected from research done by the
International Multiple Sclerosis Genetics Consortium (IMSGC) and the
Welcome Trust Case Control Consortium 2 (WTCCC2). Information about
the different cell types was collected from the ENCODE project (more
information in section 2.8.2). The Genomic HyperBrowser was used to
do all analyses. The enrichment was calculated as the ratio between the
proportion of a state covered by MS, and the proportion of everything
except the chromatin state covered by MS. In other word, they compared
the overlap between MS and the chromatin state with the overlap of MS
and regions outside that chromatin state. To find out if the overlap was
higher than expected by chance, they created a null model where the
location of individual chromatin intervals varied randomly and the MS
regions were fixed. Then they compared the real data overlap with 20000
Monte Carlo samples of the null model. The chromatin states they looked
at were active promoter (AP), weak promoter (WP), poised promoter
(PP), strong enhancer (SE), weak enhancer (WE), polycomb repressed
(PR), heterochromatic (H), insulator (I), strong transcribed (ST), weakly
transcribed (WT) an repetitive/CNV (Rep/CNV).
Results
On a global scale the enrichment values varied a lot, from 0.34 (lowest)
in H, to 3.07 (highest) in SE. But the overlap between MS and AP, WP,
PP, SE and ST was statistically significant. The chromatin states with
the significant overlap on global scale were also the ones with the highest
amount of significant bins, where the bins are chromosome arms. High
overlap between MS and active chromatin states in B cells is not necessary
an indication of any relation between the two. Therefore tests was also done
with hepatocytes, fibroblasts and keratinocytes, which are thought not to be
relevant to MS. This showed that in some chromatin states, MS overlapped
more than by chance in all cell types. But the number of significant bins and
the enrichment value tended to be higher in B cells. In AP, SE, WE and ST
regions the overlap between MS and B cells was significantly higher than
the other cell types.
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2.8.2 An integrated encyclopedia of DNA elements in the
human genome
The Encyclopedia of DNA Elements (ENCODE) project was started in 2003
and aims to describe all functional elements encoded in the human genome.
Some of the elements mapped are RNA transcribed regions, protein-coding
regions, transcription-factor-binding sites, chromatin structure and DNA
methylation site. After mapping these regions, they found that 80.4% of
the genome was covered by at least one ENCODE element. RNA covers the
biggest part of the genome.
Transcription-factor-binding sites provides a way to explore chromatin
properties. Transcription factors often have more than one function, it
can bind variations of genes and DNA sequences and different patterns of
chromatin marks.
The database with GWAS SNPs is growing fast, but 88% of associated
SNPs are found in noncoding DNA. They compared 4860 SNPs believed to
be phenotype specific, with 4492 SNPs organized in the National Human
Genome Research Institute (NHGRI) GWAS catalogue. The result was that
12% of SNPs overlap with transcription-factor-occupied regions, and that
34% overlap DHS regions.
The new elements found in this research show a statistical link with
sequences connected to diseases in humans, thus these elements can help
understanding of the diseases.
2.8.3 Systematic Localization of CommonDisease-Associated
Variation in Regulatory DNA
Themajority ( 93%) of disease- and trait associated variants emerging from
GWAS studies lie within noncoding sequences. It was defined an average of
198180 DHSs per cell type, then 5654 noncoding genome-wide significant
associations (5134 unique SNPs) was looked at. These SNPs covered for
207 diseases and 447 quantitative traits.
This gave an enrichment of 40% GWAS SNPs in DHSs, where 76.6% of
all noncoding GWAS SNPs either lie within a DHS (57.1%, 2931 SNPs) or
are in complete linkage disequilibrium (LD) with SNPs in a nearby DHS
(19.5%, 999 SNPs). To confirm these numbers they used variants from the
1000 Genomes Project on individuals of European ancestry. Here they
found significant enrichment for both SNPs within DHSs, including for
variants in complete LD with SNPs in DHSs.
GWAS SNPs was the classified into three groups, non replicated,
internally replicated (confirmed in a second population in the initial study)
and externally replicated (replicated my an independent study). This
showed that externally replicated SNPs had higher enrichment in DHS than
the internally replicated SNPs, which had higher enrichment than the non
replicated SNPs. Almost 70% of the externally replicated SNPs was found
in DHSs. This shows that many SNPs are functional and that unreplicated
and weaker associations may hide the true enrichment between SNPs and
DHSs.
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Many disorders have been linked with things happening in early
gestational stage, and hence the DHS regions with GWAS variants were
checked for activity during fetal stages. 88.1% of the noncoding SNPs was
found to lie within DHSs active in fetal cells and tissues, and 57.8% of DHSs
containing those SNPs are active in both fetal and adult cells. While 30.3%
are only in the fetal stage.
2.8.4 Chromatin marks identify critical cell types for fine
mapping complex trait variants
The idea is that if trait-associated variants change regulatory regions,
they should fall within chromatin marks in relevant cells. Therefore 15
chromatin marks were examined, and that showed that those highlighting
active gene regulation were phenotypically cell type specific.
It was assumed that variants close to or directly under tall chromatin
mark peaks in specific cell types might be involved in cell type specific gene
regulation, and that variants far from chromatin mark peaks are much less
likely to have a direct role in gene regulation.
Only traits with at least 15 reported associations in European popula-
tions were selected, and cropped by LD. This gave a set of 510 indepen-
dent SNPs associated with 31 diseases. Defining the genomic locations and
heights of 15 chromatin marks in 14 cell types, gave 4 chromatin marks
with significant phenotypic cell type specificity. The significant ones were
H3K4me3 andH3K9ac, which both are known to highlight active gene pro-
moters. To check the reproducibility, 6 different chromatin marks in 38
different cell types was collected from the Epigenomics project. Again the
H3K4me3 was the most informative mark. The H3K9ac was much less sig-
nificant, which may be due to fewer cell types analysed. Another test were
done, where they shifted the chromatin peaks locations. This resulted in a
lowered significance and hence it suggests that it is phenotypically associa-
tion and not close proximity to gene structures that gives the score.
Chromatin was divided into two groups, those falling within nearby
promoter regions, and those falling outside of promoter regions. This gave
an enrichment of H3K4me3 in strong and disease associated enhancers
when redoing the analyses, although H3K4me3 markers are generally not
thought of as being enriched in enhancers.
37 SNPs associated with LDL concentration was tested for overlap with
H3K4me3 marks in different cell types to confirm the results. The results
showed that the 37 SNPs implicated a total of 1501 H3K4me3 peaks in 34
different cell types, where the most significant cell type was adult liver
tissue. This corresponds with the idea that these variants should imply
regulatory activity within the liver.
31 SNPS associated with rheumatoid arthritis was also tested against
H3K4me3 marks. This found 1328 peaks in 34 cell types, with the most
significant association in CD4+ T cells, in particular CD4+ regulatory T
(Treg ) cells. The phenotypically similar CD4+ memeory cells were also
highly significant. Trying the same for newer SNPs gave an increased
significance of the enrichment for CD4+ Treg cells.
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In certain cases it is possible that several cell types could be implicated
in a disease. When looking at 67 SNPs for type 2 diabetes, it was found
a total of 2776 H3K4me3 peaks within 34 different cell types. With the
most significant being pancreatic islets and the liver. Combining these to
cell types gave an increased significance, even more significant than the
cell types individually. That combination was also more significant than all
other possibilities of paired cell types. Removing one of them, increased the
significance for the other. Both liver and islet cells are known to have a key
role in mediating glucose synthesis, insulin secretion and diabetes.
Discussion
It was found that chromatin marks highlighting regulatory regions, such
as H3K4me3, H3K9ac and DHSs, overlap with phenotypically associated
variants, and that this overlap is phenotypical cell type specific. It also
supports the hypothesis that many complex disease and trait alleles might
act by influencing gene regulation in a cell type specific manner. The
approach used is sensitive to the diversity and number of cell types
analysed, but it might still be used to connect phenotypes to specific
cell types or mapping phenotype associated SNPs to potential regulatory
variants.
2.8.5 Predicting Cell Types and Genetic Variations Con-
tributing to Disease by Combining GWAS and Epi-
genetic Data
Background
“Asthma is a chronic inflammatory disease, characterized by reversible
airway obstruction and increased bronchial hyperresponsiveness” [18].
There have been many GWAS studies on asthma due to the estimate that
about 35%-80% of the variation in the risk of asthma is genetic variation
based. These studies have found a large set of SNPs significantly more
frequent in asthma patients than in the healthy control group. But linking
the asthma SNPs and development of disease is not simple, this is because
the majority of the SNPs identified are in non-coding regions. And hence
they have no expected phenotype or function. Location of enhancers
such as H3K4me1 and H3K27ac has been shown to be highly cell type
specific, combining that with the knowledge that disease-associated SNPs
are enriched in enhancers, may be used to connect cell types to diseases.
This would be done by finding what enhancers the SNPs are enriched in.
Results
All known asthma SNPs were collected from the GWAS integrator database,
giving a total of 131 SNPs. Based on HaploReg the tight genetic linkage to
these SNP was also collected. As a control set, SNPs not associated with
asthma were used. It was found that the asthma SNPs are highly enriched
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in coding sequences compared to the control SNPs. However the biggest
amount of asthma SNPs are in introns and intergenic regions, non-coding
regions known to hold enhancers. It was also found that in CD4+ T cells
there is a significant enrichment of asthma SNPs in promoter and enhancer
associated regions. It was shown that the genomic location of enhancers
marked by H3K4me1 was primarily determined by cell type.
All enhancers were collected into groups, so that there was one group
for each cell type, ADM stem cells, liver cells, kidney cells, adipose
nuclei, skeletal muscle cells, brain cells, breast cells and CD4+ cells.
For these groups it was determined how many of the asthma-associated
SNPs were found in enhancers, and calculated the enrichment. The
biggest enrichment (2.11) was found in CD4+ T cells, there was also found
enrichment in liver, adipose nuclei and adipose stem cells. While there
was a very low enrichment in skeletal muscle, breast myoepithelial and
brain cells. This makes sense as these cell types are believed not to be of
importance to asthma. Of the 884 SNPs that fell into enhancers in one
or more of the eight tissues, 443 were found in only one cell type while
39 were found in all eight cell types. By looking at the enrichment of
asthma SNPs in enhancers in CD4+ T cells compared to how many cell
types has this enhancer, one could see that the fewer cell types, the higher
the enrichment. Highest enrichment was therefore found in enhancers
unique to CD4+ T cells, while the enrichment in skeletal muscle cells
decreased with stricter uniqueness to enhancer. It was also found that
asthma associated SNPs located in enhancers overlap with Transcription
Factor Binding Sites (TFBS) four times more often than those not located
in enhancers. Thismeans that disease SNPs in non-coding regions aremore
likely to be functional, andmay do so by disrupting binding of transcription
factors.
Discussion
It is difficult to predict how genetic variations affect disease development,
as the effect may be limited to a certain cell or effected by environmental
factors. To help void these problems, the techniques from this article may
be used. The authors suggest that this method may be even more powerful
if all SNPs were reanalysed, and then limiting themethod to the SNPs active
in the genomic regions of the cells of interest.
2.8.6 Next-generation sequencing in understanding com-
plex neurological disease
Techniques
The first complete read of the human genome was obtained in 2003, and
since then there has been an explosion of people who have had their
genome fully or partially sequenced. Only recently, though, has it been
possible to use it on complex diseases. Complex diseases are defined
as diseases where multiple factors affect the risk factor such as multiple
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genetic and environmental factors, and where these factors will affect
individuals differently. GWAS research has been extremely efficient in
finding genetic risk loci, but very few of these have a direct detectable effect
on gene expression. They do more commonly have other regulatory effects,
such as influencing gene expression. For example, 47.6% of some SNPs are
predicted to alter transcription factor binding, while only 7.3% are shown
to alter gene expression. For disease associated SNPs there has not yet been
found a function, and that is believed to imply that the true casual variant
is likely to be a nearby variant.
The usual way to use next-generation sequencing is to align multiple,
short, overlapping reads of fragmented DNA against a reference genome. If
no such reference genome exists, it can be assembled “de novo”. Another
method of sequencing is whole-exome sequencing. This uses the same
method, but complementary strands to known exons are used to extract
fragments covering exonic regions prior to sequencing. This makes the
analysis cheaper and less computationally demanding because it requires
less sequencing. A drawback is that it will only capture variants inside
exons, and hence lose any causative variants elsewhere. This of course is
not optimal as it has been shown that the majority of variants are located
outside the exons. Many causative variants for complex neurological
disease may be found by next-generation sequencing, but because of the
high number of variants the chance for false positives is also high. For
example, whole-exome sequencing on MS patients did find more than
58000 variants in each individual. This shows the need for integrating
information and knowledge fromGWAS to help select plausible candidates.
As more genomes get sequenced, it will become easier to understand how
complex neurological diseases works.
Next-generation sequencing can also be used for sequencing mRNA.
This is done by using probes for polyadenylated mRNA and reverse
transcriptase to generate cDNA, which then can be sequenced using
conventional techniques. It is very important that this type of sequencing
is done on the correct cell types, as there is evidence that genetic effects on
expressions may be cell type dependent. So far the use of such sequencing
has been very limiting, but in the future it may become easier as more
information of the normal human brain tissue is mapped. This is done
by collecting samples port mortem from different development stages in
humans. The main difficulty is to collect tissue, since that means autopsy
samplesmust be studied, and that is generally a poor replacement for living
tissue, specially since RNA very easily degrades fast when dead.
Another use of next-generation sequencing is chromatin immunopre-
cipitation. In this method, a protein of interest bound to fragments of DNA
is separated using antibodies. The DNA fragments can then be sequenced
and mapped back to reference genome. This provides a map of where that
protein is binding, and hence provides data on functional genomics. It has
been shown that a significant amount of GWAS associated SNPs lie in tran-
scription binding sites. So this method can give an idea on how genetic
variants effects disease development. A downside to this method is that it
needs a strong theory that can determine the target of the antibody used.
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“Epigenetics is the study of reversible modifications to the structure of
DNA associated with gene expression differences.” [20] Some think that
epigenetic variations may be the cause of several complex diseases. Next-
generation techniques can be used to search for regions of the genome
enriched for modified forms of chromatin. Epigenetics is believed to be
cell and time dependent, and hence selecting correct tissue and timing is
important.
Use
Identifying causative variants in previously undiagnosed or complex dis-
eases has already been done, and hence it might be said that the most di-
rect use is withinmolecular diagnostics. Next-generation sequencing is also
likely to have an important role in diagnosis of complex phenotypes. An-
other use is risk prediction and genetic counseling, where the popularity of
direct to consumer (dtc) shows the public’s interest in that. Companies like
23AndMe and Navigenics are selling self tests, that then are analysed and
profiled for common diseases through SNP genotyping. See section 2.4.3
for more information on this subject. So far, personalized medicine has
yet to bear fruits, but next-generation sequencing may in the future allow
for treatments to be tailored to individual patients in a way that previous
genetic techniques could not, as noted in section 2.4.
Next-generation sequencing techniques have produced huge amounts
of data. This demands for efficient statistical methods, that will allow for
quicker and more powerful analysis of the data.
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Method
In this chapter the theory behind the tool and algorithm will be presented.
The first section is about how it is possible to store and think of genetic data
as mathematical segments over the natural numbers, and how that makes
it possible to do analyses based on mathematical models. The final section
will cover the analyses used by the tool in the HyperBrowser.
3.1 Genomic Tracks
There are many different ways to represent genomic information, and as
with most new fields, there is no general consensus on how this should be
done. In bioinformatics, standards such as ensemble, refseq and uniprot
exist side by side. This can make it hard to compare and duplicate results
and tests. In ensemble there may be several names for the same gene at
almost the same position, if not the exact same position. To be able to work
with the different standards it may therefore be necessary to use translation
programs or compare positions to find the equivalents, but there is no
guarantee that such an equivalent exists. To avoid this, the HyperBrowser
uses tracks as described in this section. That way, one only have to compare
positions. It stores chromosome, position and the alleles. Figure 3.1
shows how some genomic tracks can be visualized. Figure 3.1a shows
genetic points, a point might be the position of a single allele mutation,
or other points of interest. Figure 3.1b shows representation of genetic
segments. A segment can for example be a exon or intron. Each segment
represents a specific place on the track. Figure 3.1c represents the same
as fig. 3.1a but this time each point is given a weight or value. One of
the uses for this may be if several tracks are merged together, then each
point can be valued according to how many of the tracks have a point
in that position. Figure 3.1d shows weighted or valued segments. The
use is about the same as fig. 3.1c. To store the genomic tracks, it is only
necessary to keep the relevant info. That is the boxes or thin vertical lines
in fig. 3.1. When HyperBrowser processes a track, it creates a track object
containing information about that track. From such a track object it is
possible to collect all the segments and points as arrays. That is, for each
chromosome it will return one array containing the start positions and one
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(a) Points (P) (b) Segments (S)
(c) Valued points (d) Valued segments
Figure 3.1: Different ways of visualizing track types. Figure 3.1a may be a
genetic point, like a SNP. Figure 3.1b may be a SNP with flanks, creating a
segment of DNA. Figure 3.1c may be point given a certain value based on
some test. Figure 3.1d may be a segment given a certain value based on
some test.
array containing the stop positions. These arrays are linked in such a way
that the start position at index i in the start array, belongs to the stop
position at index i in the stop array. The start array is always sorted, and
hence the equality follows like this:
startsAsArray[i ] ≤ startsAsArray[i +1] if overlap allowed (3.1)
startsAsArray[i ] < startsAsArray[i +1] if overlap not allowed (3.2)
The stop array can not be assumed to be sorted, since the stop position
at index i is linked to the start position at index i . The exception is if no
overlap is allowed, then one can assume it to be sorted as well. If overlap is
allowed, the stop position at index i +1 may very well be smaller than the
one at index i . The positions in the arrays can de seen upon as positions
along the natural number line, and hence one can start to look at this a bit
mathematically. The ideas to the definitions used are based on the work
done in [19], but not identical. It has been modified and simplified to what
is needed for this thesis.
The definition of a metric space d on the natural numbers is as follows,
given ∀x, y, z ∈N the following holds:
1 :d (x, y)≥ 0 (3.3)
2 :d (x, y)= 0 ⇐⇒ x = y (3.4)
3 :d (x, y)= d (y, x) (3.5)
4 :d (x, z) ≤ d (x, y)+d (y, z) (3.6)
A metric space on the natural numbers is the regular distance function,
which works well for calculating the size of a segment or a point:
d (a,b)= |a −b|, a,b ∈N (3.7)
32
3.2. THE ANALYSES
This gives the size of a segment going from a to b, where b not inclusive.
A point is when b = a+1. This means that a segment will consist of a subset
S of natural numbers, which can be defined as:
S(a,b)= {s ∈N | a ≤ s < b} (3.8)
And we define a point to be:
P(a) = S(a, a +1) (3.9)
By defining it like this we can say that a segment consists of at least
one point, and a segment is a point if and only if it has size one in the
metric system. Take for example, a segment starting at 1 and ending at
3, inclusive. That gives S(1,4) = {1,2,3} and d (1,4) = |1 − 4| = 3. A point
is then P(2) = S(2,3) = {2} and d (2,3) = |2− 3| = 1. This shows that a point
can be within a segment; it also allows for overlapping segments. Another
practicality is that it allows tracks to contain both segments and points, as
long as it is represented as segments. This fits well with how one can collect
the tracks from the HyperBrowser, as arrays of integers, and this metric
space is the basis which the overlap algorithm described in section 4.2.3 is
built around.
By representing these tracks mathematically it is also easy to generate
random reference tracks. The reference track can be used to say whether
the similarities are greater than they would be by chance. The randomized
track can be generated fully randomized, or it can be generated according
to biological rules to make it more realistic.
3.2 The analyses
There are mainly five analyses that can be selected in the tool, and used for
different statistical purposes. The following sub-sections are meant to give
an overview of what kind of tests the different analyses does. These analyses
were already implemented inside the HyperBrowser, but they could only
be selected individually before. For simplicity T1 and T2 will represent two
arbitrary tracks. Theymay very well be looked upon as trait track (T1) and a
random subtype of a genetic region (T2). Each of the analyses below will be
done for each chromosome in each of the tracks separately. Hence it does
not work on the full track as a whole, but it takes chromosome one in T1
against chromosome one in T2, then chromosome two against chromosome
two, and so on.
There is a option for setting a global p-value threshold when selecting
a hypothesis testing as analysis. The tests will run until a p-value is found
that is better than the threshold, or until one of the other criteria set in the
code is met. The other criteria are, 20000 test runs, or 10 test samples with
better results than the real case.
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(a) Binary normalization basis
(b) Coverage depth normalization basis
Figure 3.2: Shows how the different normalizations are calculated based on
overlap between segments
Figure 3.3: Shows how regions touched between T1 and T2 is calculated, 4
segments of T1 touches a segment in T2.
3.2.1 Binary and coverage depth normalization
TheHyperBrowser uses two different different ways of calculating the value
of a certain position on a track. In this case one can imagine a track T3
which contains T2 and all the other subtypes for that region, where the
tracks in T3 are allowed to have overlapping segments. T3 then becomes
the normalization track that is used to say something about the size of T2
compared to all the other subtypes. If T2 is large in T3, then one should
expect that T1 overlaps more with T2 than with the other tracks in T3 if it
was random. Thus the T3 is used to find out if T1 overlaps more with T2
than size accounts for.
Binary and coverage depth are two different ways of defining the
specifics of T3. With binary T3 flattened down, it ignores how many
segments might be overlapping and just stores if there at least one segment
there or not. Figure 3.2a visualizes how the binary track is calculated.
Coverage depth values each point according to howmany segments was
overlapping there. Hence if T3 has 4 segments overlapping at position
1000, that position is given value 4. Figure 3.2b visualizes how coverage
depth is calculated.
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3.2.2 Regions touched
Regions touched can be calculated in two ways. It can be done by looking
at the entire segment, or it can be done by looking at the midpoints. If
regions is selected it will count how many segments in T1 touch a segment
or point in T2. If the segment in T1 touches anything in T2 it is counted
as one, and it moves to the next segment in T1. This means that if T1
contains 40 segments, regions touched on a global scale will be between
0 and 40 inclusive. Figure 3.3 shows how 4 segments in T1 touch segments
in T2. The midpoints in the segments in T1 will be be found if midpoints
is selected, and the number of midpoints touching any segments will be
counted.
This analysis also allows for hypothesis testing. It then generates a large
amount of random segments or points, depending on what is chosen of
midpoints or regions. The result is presented as a p-value, saying whether
the result is higher than what can be expected.
3.2.3 Enrichment
Enrichment says something about the relation between how much of T1
is inside T2 compared to outside T2. The mathematics behind it is best
explained by looking at the actual calculation. For simplicity we define tp,
fp, fn and tn as:
• tp is the intersection of T1 and T2
• fp is how much of T1 that does not cover T2
• fn is how much of T2 that does not cover T1
• tn is how much of the whole genome that does not cover any of T1 or
T2
This creates a set of variables that makes it possible to say something
about the relations between these two tracks.
1i nsi de2=
t p
f n + t p
(3.10)
1out si de2=
f p
f p + t n
(3.11)
enr i chment =
1i nsi de2
1out si de2
(3.12)
In this case the result is T1’s enrichment in T2. For enrichment, one can
choose to use coverage depth or binary normalization as basis for T2.
3.2.4 Hypothesis Testing
Hypothesis testing checks if the enrichment of T1 in T2 is larger than
expected. This is decided by randomly generating tracks, and then
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comparing it with the original result. This type of testing takes many
statistical variables, but for this tool they have been preset in the code and
hence hidden from the user. What the user can choose is whether it should
be normalized based on binary or coverage depth.
3.2.5 Count Points
This analysis counts the number separate segments in T2. This means that
if two segments overlap, they will be merged and counted as one.
3.2.6 Average Segment Length
This analysis calculates the average segment length in T2.
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Implementation
This chapter will cover the implementation of the tool and the new
overlap algorithm. It will be explained how the tool works, and to some
extent cover how it interacts with the HyperBrowser and how it uses the
Gw asB at chLi nes class. Then the Gw asB act hLi nes class will be described
in some detail, including the methods and how to expand it. The final
section will be covering the new overlap algorithm, how it works and how it
was compiled into efficient C code.
4.1 Genomic variation analysis tool
The tool is built in such a way that when it runs, it creates objects of a
class named GwasBatchLines. Each genetic region will create a new object.
The object keeps track of what type of analyses should be run with which
settings, and it keeps track of what type of tracks belong to what analyses
and regions. The next two sub-sections will explain the implementation of
the tool and the method that creates the objects.
4.1.1 Inside the tool
Making selections
The tool is created as a part of the HyperBrowser, and hence it is web
based with a graphical user interface. This also means that it inherits a
lot of methods and structure from the HyperBrowser. Everything has to be
created within a class, and that class needs some methods. One method is
the g et Tool N ame, which returns the name of the tool as a string. Another
method is the g et Input BoxN ames, this one returns a list of strings. Where
each string is the name or text of the selection boxes in the tool.
Then comes the g etOpt i onsBoxY (pr evC hoi ces), the Y represents the
number of the box. And pr evC hoi ces is a collection of the previous selected
options. It is this tool that creates the drop-down boxes and checkboxes.
The drop-down boxes are created if the method returns a list of strings,
where then each string becomes an option in the drop-down menu. The
string selected from user is then placed in the pr evC hoi ces variable. This
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implies that each of these methods have access to previously selected
choices. The checkboxes are created when it returns an OrderedDict with
tuples. A OrderedDict is a subclass of dictionaries in python. It supports
the usual methods for dictionaries, but it also remembers the order the
keys were first inserted [2]. Checkboxes can be grouped together, such that
all genetic regions can be one group and the analyses in another group.
One OrderedDict can contain many tuples, and each tuple becomes one
checkbox. The tuple consists of one string, the text, and one boolean. If
the boolean is preset as True, the box is pre-selected, and if it is False it is
unselected. The string of the tuple is also the key to each box, and the key
will return True or False depending on if the box is selected by the user or
not.
The user should not have to think about things not relevant for the
selection made. For example should the user not need to consider what
type of normalization to use, if all he wants is the get the average segment
length of some regions. This is solved by letting the methods return None
if some condition is not met. The condition then being for example that an
analysis needing normalization is selected before the user has to choose
normalization. If the condition is met, it should return the menu like
previously described.
The execute method
The execute method is called when the execute button is clicked. The
execute method takes all the selections as input. For this tool the execute
method analyses the path to the trait track, and collects information like
track type and name. Then it uses that information together with the
choices made by the user to set up the objects. This is done in a separate
method, which takes the needed information as input. A new object is
created for each genetic region to analyse, and each object is stored in a
dictionary with the region as key. It then runs through the choices done
by the user, and sets variables in the object to True according to what
is selected. It returns the dictionary with the objects back to the execute
method.
Then one and one object is sent to another method which collects all
the subtypes for the genetic region in a list. For each subtype it collects all
the batchlines from the object. It then inserts the subtype to each batch
command and sends it to the HyperBrowser specific r unB at chLi nes. This
method returns a ResultDict for each batch command. A ResultDict is a
HyperBrowser specific python dictionary with some extended functionality,
such as a method to get the global result for all chromosomes.
It then collects all the global results, the result from the entire genome
and not just in one chromosome, into a table. Where each row contains
the result for one subtype, and the columns are the analyses. This table is
written to a web page, by the use of methods writing tables in html. The
t abl e Header takes a list strings and generates the header line of the table.
Each element in the list is the header for a new column. The t abl eLi ne
creates the rows, and too takes a list of strings, where each string is written
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to a new column. Here, each string becomes the html code for a link,
pointing to a subpage with more detailed information about the results.
By using the g et Li nk method on the path to the subpage, one gets the html
code for a link to that element. The g et Li nk method takes in a string, which
becomes the text for that link.
Another method uses the information from the table to draw the graphs
using HyperBrowser methods again. First a path is created to a file, then
the method openRF i g ur e is used on that path. That allows the user to
plot to the path using regular R commands. When the plot is done, one
uses the file with cl oseRF i g ur e. The plots collect the 20 subtypes with the
highest enrichment and highest amount of regions touched and plots them
in separate graphs. If there exists some p-values form hypothesis testing,
this is plotted on top of the enrichment graph. If only hypothesis testing is
done, then that is plotted alone.
4.1.2 Inside the GwasBatchLines class
GwasBatchLines is a class used to create an object for each genomic region
that is to be analysed. It contains a lot of different boolean variables, saying
something about what type of analyses are supposed to be ran on that cell
type. Following will be an explanation on how that class works, and how it
can be expanded with other genomic regions. So the following paragraphs
are written to make it easier for future developers to understand how this
class works. That will also make it easier to add genetic regions or to
expand with more tests. For the impatient reader, the i ni t method and
the g etUni on are the ones explaining how to add genetic regions, while the
i ni t method and the two sections about batchlines are needed for adding
new analyses.
The init method
The init method can be seen in listing 4.1, and it is run when a new instance
of the class is created. It accepts six variables, where the first is a string of a
path to a trait track. It may be one stored in the HyperBrowser database, or
it may uploaded and created by the user and hence be found in the history
panel. There exists two different types of paths to tracks; one is to the
database, and the other is a html link to the place the track is stored in
history. They can look like this, where the first line is for HyperBrowser
database, and the second line is the first part of a html link.
1 Private:GK:MS3dec12Base :GwasSnps:8 − Asthma_SNPs.txt
2 galaxy:bed: /usit/invitro/data/galaxy/galaxy−dist−hg−personal/database/ . . .
Listing 4.2: Hyperbrowser track paths
It also takes in t r ack N ame as a string; this is the last part of the path
to the trait track. This means that from the example above it would be 8 -
Asthma_SNPs.txt for the path to the HyperBrowser database. This is done
to make it easier to present the results for that object later. The t r ai t Tr ack
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1 def __init__(self, traitTrack, trackName, NAME, trackType, version, ←-
chromatinState = ' ' ) :
2 self .NAME = NAME
3 self .trackType = trackType
4 self .VERBOSE = True
5 self .touched = False
6 self .enrich = False
7 self .testing = False
8 self .observed = False
9 self .obsExp = False
10 self .mid = False
11 self .allreg = False
12 self .binary = False
13 self .coverage = False
14 self .countpoint = False
15 self .avgseglen = False
16 self .chromatinState = chromatinState
17 self .traitTrack = traitTrack
18 self .trackName = trackName
19 self .version = version
20 self .tf1Touched = ' '
21 self .rawStat = ' ThreeTrackT2inT1vsT3inT1%sSta t '%version
22
23 self .FT = ' 1 .0 '
24 self .GlobT = ' 1 .0 '
25 self .GT = ' 0.01 '
26 self .numResamplings = ' 3 '
27 self .mcParams = 'maxSamples=2000,numResamplings=%s , numSamplesPerChunk←-
=25 , '%self .numResamplings+\
28 'mThreshold=10 , f d rC r i t e r i on=simultaneous , fdrThreshold=@FT,←-
g lobalPvalThresho ld=@GT '
29
30 self .DHSUnion = ' P r iva t e :GK: Psych :DHSs '
31 self .DHSUnionCoverageDepth = ' P r iva t e^GK^Psych^DHSCoverageTrack '
32
33 self .TFUnion = ' P r iva t e :GK:MS4: EncodeTfsExceptVdr '
34 self .TFUnionCoverageDepth = ' P r iva t e^GK^MS4^ ←-
EncodeTfsExceptVdrCoverageFunction '
35
36 self .ChromatinUnion = ' P r iva t e : Anders : Chromatin State Segmentation : '
37 self .ChromatinUnionCoverageDepth = ' P r iva t e G^WAS^ Chromatin^←-
CoverageFunctionTracks ^ '
38
39 self .H3K4me3Union = ' P r iva t e :GK: Psych :H3K4me3 '
40 self .H3K4me3UnionCoverageDepth = ' P r iva t e^GK^Psych^←-
H3K4me3CoverageTrack '
41
42 self .enrichUnion, self .testUnion, self .testUnionFloat = ←-
GwasBatchLines .getUnions(self, NAME)
Listing 4.1: Gwas Batchlines init method
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is the actual path or link. The third variable is N AME , which tells what type
of genetic region this analyses is to be run on. The name will be one of the
genetic regions the user has selected run the analyses on, there will be a new
object for each region selected. The variable t r ackT y pe, is used later to tell
the system what type of track the trait track is. If it is selected from the
database, it is one type, while if it is selected from history it can be different
types of tracks. From the example above, the track type for the history path
would be bed. The version says something about whichmethod will be used
to calculate the coverage depth. It will either be V er si on2 or V er si on3, if
it is V er si on2 it will use the old statistic, while V er si on3 will use the newer
statistic explained in section 4.2. This variable changes the r awSt at string,
and also affects which one of the merged region tracks that will be used.
This option is kept in the code for analysing speed and correctness, but the
choice is not included in the tool as V er si on3 is default. The final input is
the chr omat i neSt ate; this one is there to make sure the merged track for
the correct chromatin state is returned.
The boolean variables are used to determine what batch lines are to be
returned. Some will be set to true depending on selections made by the
user in the tool, and then when the tool calls g ener at eB at chLi nes it will
run through a list of if else tests to determine which commands to return.
The F T , Gl obT , GT , numResampl i ng s and mcPar ams are different
variables used when running statistical analyses, and they are copied into
the batch line further down in the code. They are extracted like this so that
it is enough to modify it once for all different analyses. Line 30 to 40 are
paths to different tracks used for the different genetic regions. They are
sorted in groups based upon region. Hence the DHS are grouped together,
and the same for TF, Chromatin and H3K4me3. The first one is pointing to
all relevant subtypes of that region and at the same path is a track with all
the subtypes merged together. This merged track can contain overlapping
segments. The second track is the merged track, but without overlapping
segments. How that track looks will be explained more in section 4.2.1.
Another detail is that the : has been swapped withˆ . Some analyses in the
HyperBrowser cannot use : as a divider, and because of this it it has been
swapped withˆ.
The final line, line 42, sets up which of the merged tracks are to be used
later based on genetic region selected and which statistic is used.
To add new genetic regions, they will have to be added like the previous
ones: one which hold the path to the subtypes, and on containing the path
to the merged track without overlap if it is to be included in testing the two
algorithms.
To add more statistics, more boolean variables have to be added to the
top, so they can be set be set from the tool.
The getUnion method
This method is there to make it easier to add more genetic regions. Its main
purpose is to return the two correct paths, which is dependent on genetic
region and version of the statistic. The method can be seen in listing 4.3. It
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1 def getUnions(self, NAME, version) :
2 i f NAME == 'DHS ' :
3 i f version == ' Version2 ' :
4 return self .DHSUnion, self.DHSUnionCoverageDepth
5 e l s e :
6 return self .DHSUnion, self.DHSUnion.replace( ' : ' , '^ ' )
7 e l i f NAME == 'TF ' :
8 i f version == ' Version2 ' :
9 return self .TFUnion, self .TFUnionCoverageDepth
10 e l s e :
11 return self .TFUnion, self .TFUnion.replace( ' : ' , '^ ' ) ,
12 e l i f NAME == ' Chromatin ' :
13 union = self .ChromatinUnion + self .chromatinState
14 unionCoverageDepth = self .ChromatinUnionCoverageDepth + self .←-
chromatinState
15 i f version == ' Version2 ' :
16 i f ' Act ive ' in self.chromatinState :
17 unionCoverageDepth = unionCoverageDepth + 'V2 '
18 return union, unionCoverageDepth
19 e l s e :
20 return union, union.replace( ' : ' , '^ ' )
21 e l s e :
22 i f version == ' Version2 ' :
23 return self .H3K4me3Union, self .H3K4me3UnionCoverageDepth
24 e l s e :
25 return self .H3K4me3Union, self .H3K4me3Union .replace( ' : ' , '^ ' )
Listing 4.3: getUnion method
accepts the genetic region and statistic version, and uses that to determine
which paths are needed for this case. If the statistic is version two, it returns
the path to the merged track without overlap, otherwise it will return the
path to all the subtypes.
Note that there is an extra test if the region is chromatin. That is
because the name of the merged track without overlap for active promoters
in chromatin is slightly different than the rest, and all the chromatin states
can use the same base paths. It is also worth noticing that in the path to
the merged track with overlap, : is replaced with ,ˆ for the same reasons as
explained earlier.
When adding another genetic region to the class, it has to be added in
this method as well. This is done by adding another test, checking for this
new region and returning the paths according to the tracks for this region.
The batchlines
All the different batch lines are put into separate methods, returning a list
of strings containing the batch commands. These batch commands vary in
size, but the structure is similar. Following is a small example of on how a
method may look:
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1 def batchEnrichBinary(self) :
2 return [ '@bins =%s'%self .traitTrack, '@TNs= ' , '@TNunion=%s'%self .←-
union, \
3 'hg19|%s|@bins|@TNs|@TNunion|DiffRelCoverageStat( '%self .←-
trackType +\
4 'globalSource=chrs,tf1=TrivialFormatConverter,tf2=←-
TrivialFormatConverter) ' ]
Listing 4.4: Example of batch commands in method
This is the batch line for finding the enrichment with binary normaliza-
tion. As can be seen, it inserts the different variables at the needed places,
and it uses the variable union. That method does not need to do any testing
for genetic region, due to the method getUnion earlier. Also notice that the
element in position 1 in the list is not set. That empty variable is always
positioned at index 1, and will back in the tool be pointing to one and one
subtype for the actual genetic region. The position will always be index one
to avoid being dependent of the name of the variable.
By adding another method with an appropriate name, that returns the
batch command list, it is possible to add more analyses. What needs to be
remembered is to make the trait track andmerged track path dependent on
the variables in the i ni t method and not static. And to have the variable
that will hold all subtypes at index 1.
The generateBatchLines method
This method is the method that actually returns the correct batch com-
mands. It is called from the tool after all the booleans have been set. Then
it goes through a set of if else tests and calls the methods holding the ap-
propriate batch commands. The commands are added to a dictionary, with
the keys as the name of the analysis. It returns a dictionary containing lists
with strings. Each key has one list, each list is the batch command to one
analysis, and each list contains several strings (as seen in listing 4.4).
When adding new analyses to the tool, new tests have to be added to
this method. The new tests will have new booleans, and if they are true, it
should call the method returning the commands. The commands should be
added to the dictionary under an appropriate unique key.
4.2 Genomic track overlap algorithm
Some of the analyses in the tool normalize the result based on local results
from all subtypes. As explained in section 4.1.2 and seen in listing 4.1, every
test region originally needed two tracks. One containing all segments with
overlap, and one containing no overlap but where each segment is valued.
Each genetic region has several subtypes and during hypothesis testing
it is needed to look at all of those as one. By merging all subtypes together,
allowing overlap and sorting on the start position of each segment, you get
what is here called the union track. Although strictly speaking it is not a
43
CHAPTER 4. IMPLEMENTATION
(a) Union before trait (b) Union into trait (c) Union in trait
(d) Trait before union (e) Trait into union (f) Trait in union
Figure 4.1: The different options for a trait segment to overlap with a union
segment. All possible overlaps for the algorithm are these six or variations
of this.
union, as it is just appending or merging all the tracks together to one since
overlap is allowed.
A flattened version of that track with valued segments, is then called
the coverage track. The weighting is found by counting the number
of overlapping segments at each position. Figure 3.1d gives a visual
explanation on how a weighted track can be viewed.
The single track without overlap is called trait track. The HyperBrowser
is written so that it is possible to request all segments from a track,
chromosome by chromosome, as a st ar t s As Ar r a y and a st ops As Ar r a y .
Both these arrays are of the type numpy.ndarray. One array holds all the
starts positions, and is sorted. The other array holds the stop positions to
the same segments, not inclusive. This gives that if the second segment
goes from 10 to 15 (inclusive), it will be stored as 10 at index 1 in the array
with start positions and 16 at index 1 in the array with the stop position.
The union track has the start values sorted, but the end values may not be
sorted as it allows for overlapping segments. The trait track will have sorted
start values and end values, as it does not contain overlap.
4.2.1 The unwanted track
Originally some of the analyses used the coverage track to do the needed
calculations. This is not optimal, as this coverage track has to be pre-
produced for each genetic region. This is a computationally heavy and slow
process, but it only has to be done once as the track then is stored on disk.
Reading a track from disk is reasonably fast. There also exists a method for
creating this track if it does not exist, but it runs very slow. The coverage
does not have overlapping segments, but instead it contains valued points
and segments.
4.2.2 The goal
To optimize the hypothesis testing and make it independent of such a pre-
made track, a new algorithm had to be made. The new algorithm should
find the overlap between two tracks with segments, one track allowing
overlap between the segments (the union track), and one track not allowing
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overlap (trait track). Thismeans that the overlap algorithm is to take in four
arrays as input, one containing the start positions of the trait track, one
containing the end positions for the trait track, one for the start positions
of the union track and one containing the end positions for the union track,
and return the total overlap between those tracks. This would take away the
need for the coverage track, and make it easier to implement new genetic
regions as they would not need to create such a track.
4.2.3 Implementing the new algorithm
Setting up the tests
The first task was to set up some test cases using nosetests. Nose is a
handy tool for writing and managing unit testing in python. It is ran by
calling nosetests, where it then scans the current directory for any filenames
starting with test. Then it calls all the methods starting with test in those
files. It also comes with handy assertion tests. The test file has to import the
program or method it is to test and nose. For the tests ran here nose.t ool s
was chosen, as that includes some more assertion tests, such as tests for
checking if equal, almost equal (which lets you set allowed error), and for
errors (checks if the correct error is raised). Below is an example of a test
written to see if the algorithm handles a union segment starting and ending
before the trait segment, as shown in fig. 4.1a. It looks like this:
1 def test_beforeTrait( ) :
2 " " "Union complet ly outs ide t r a i t , be fore " " "
3 union = [ [ 1 ] , [ 4 ] ]
4 trait = [ [ 5 ] , [ 7 ] ]
5 uStart = array(union[0 ] )
6 uStop = array(union[ 1 ] )
7 tStart = array(trait[0 ] )
8 tStop = array(trait[ 1 ] )
9 overlap = countOverlap .overlapStat(uStart, uStop, tStart, tStop)
10 nt.assert_equal(0 , overlap)
Listing 4.5: Nosetest example
nose.t ool s is imported as nt , and asser t_equal is used to make sure
that the method actually returns zero. The asser t_equal also takes an
optional variable, a string, as a message that will be printed if the assertion
fails. The variables union and trait are 2D lists, where index 0 is the list
containing starting positions for segments, and index 1 contains the end
position for the segments of that index. In this case both contain only one
segment. Then the lists are changed to arrays, and sent to the method that
will count the overlaps. It then compares the returned result with what is
known as the correct number.
There are only a limited number of different ways two segments can
overlap; these six are shown in fig. 4.1. And any type of overlap between
two tracks containing more segments, will therefore be a combination of
these. For example can a segment in the union track overlap the last part
of a segment from the trait track and the first part of the next segment.
That would be a combination of fig. 4.1e and fig. 4.1b. The first tests written
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were therefor tests for the six simple overlaps for two segments, and then
expanded for the more obvious combinations of these cases. In the end it
17 tests to make sure all cases were covered.
The test files
For simplicity, the algorithm was not constructed on the HyperBrowser,
but on a local desktop. To be able to monitor the efficiency and correctness
of the algorithm, three tracks were downloaded from the HyperBrowser to
do the tests on. All these files were downloaded as bed files, such that the
first line contains information about what track it is, and the rest contain
the segments. The information is stored column-wise, such that the first
column contains the name of the chromosome, the second column contains
the starting position of that segment, which is inclusive, the third column
the stop position, which is not inclusive, and the fourth column contains a
name.
The three main files used were two trait tracks and one union track. The
trait tracks were alzheimer SNPs and alzheimer SNPs with 50kb flanks.
The segments with 50kb flanks are 100001 long and the SNP are 1 long.
The SNPs are just a segment of length one, so for the algorithm it changes
nothing. The alzheimer files consist of 41 segments.
The union file is all DHS regions appended together into one, so
that several of the segments may overlap each other. It holds 24046672
segments of varying length.
The algorithm
The first version of the overlap method was written as simple and straight
forward as possible. The goal was just to get a something working,
something that could be improved later. It went through each segment in
the trait track, and checked each number between the start position and
the end position to see if it was a part of a segment in the union track. This
means that for m segments in a trait track of length k , and n segments
in the union track, it has to do m ∗ k ∗ n iterations to find the overlap.
Considering that k can be anything from one to many thousands, and n
can be several millions, this is too inefficient. This demands three loops,
where the outer one is for the trait segments, the middle one is for each
step in that segment, and the third is for each segment in the union track.
To increase efficiency there was added a variable remembering indexes, this
variable would remember where to start the search for overlap in the union
track. It is know that the trait track is sorted and not overlapping, and the
union track is also sorted, and thus it is easy to check if the beginning of a
segment from the trait track is larger than the ending on the segment from
the union track (as seen in fig. 4.1a). This variable is controlled by a flag, the
flag remembers if all previous endings have been smaller than the current
start position in the trait segment. If it is, the next index is stored, and the
next search starts from that index, ignoring the segments before. This gave
the correct answer for all the test cases, but when tried on a real trait track
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with all subtypes of DHS merged into the union track and alzheimer SNP
with 50kb as trait track, it took too long.
On the test computer (described in section 5.2) it took more than 300
seconds just for chromosome 5, while chromosome 4 took more than 700
seconds. Even if the test was for one chromosome only, this would not be
fast enough. Thus one loop had to be removed.
Since the segments are continuous, and based on start and stop
position, there is no need to loop through each position in the segment.
Since the stop position is not inclusive, the length of a segment is easily
calculated as explained in section 3.1. In fig. 4.1 it is shown what options
have to be considered when finding out what start position to subtract
from what stop position. This is done by, for each segment in the trait
track, looping through the segments in the union track and comparing the
segments with some tests.
The first thing to check is if the start position in a trait segment overlaps
in some way with a segment from the union track. If it does, it is subtracted
from the stop position that has the lowest value to find the size of the
overlap. This is shown in figs. 4.1b and 4.1f. If the start does not overlap,
then the stop position is checked for overlap with the segment from the
union track. If overlapping and the start being smaller than the start from
the union track segment, then the start from the union track segment is
subtracted from the stop position to give size of this overlap. This is the
same as fig. 4.1e. The final possible overlap is for union segment completely
inside the trait segment. It is checked that the start position for the union
segment is larger than the trait segment, and that the stop position for the
union segment is smaller than the trait segment. If true, then the size is
found. That is fig. 4.1c. The last option left then is for fig. 4.1d, that is
checked by seeing if the start of the union segment is larger than the end
of the stop position for the trait segment. That would mean that the rest of
the union segments will be larger than the current trait segment, and hence
the inner loop is broken, and we start over with the next trait segment.
Remember that the index for the first union segment to overlap with the
trait segment from previous round is stored, which means that the loop
does not have to start from the beginning this time. Whenever any overlap
is found, it is added to a variable keeping track of the total overlap for that
chromosome. To save memory and increase speed, xr ang e has been used
for the generating the list of indexes looped over. This method has the
benefit that it does not create the entire list of numbers, but generates a
object that returns the numbers in the list [1]. This saves memory and
increases speed for large lists such as the ones used here. The method
returns an integer which is the overlap counted.
Cython implementation
Cython is a tool for translating Python code into efficient C code. It
increases the speed drastically, and it is very efficient for methods doing
big iterations. In a way, Cython works really well with the Pareto Principle,
or 80/20 rule, that about 80% of the runtime is used in about 20% of the
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1 python setup.py build_ext −−inplace
Listing 4.6: Running the script compiling Cython
code[4]. Thismeans that 80%of the code can use Pythons flexible and easy-
to-read syntax, and then Cython can be used for the 20% of the code that
would benefit from increased speed. For Cython to have the most optimal
run time, all the types have to be specified in the code, Cython is typesafe.
This is for variables created inside the Cython code, and preferably for input
variables. Input variables do not have to be type specific, but that will affect
the runtime as it is then done by the Python interpretor [4].
The file extension used for Cython is .pyx and this file is compiled into C
code. After compilation it can be imported and used like any other Python
library. Compilation is made easy by running a small Python script. The
script can be seen in listing A.2, and is run with the command shown in
listing 4.6.
The method described in previous section, is a method that would
benefit a lot from a Cython implementation. It takes in four arrays, and
returns the overlap by looping through the arrays while calculating the
overlap of each segment. Thismethod was then pulled out into a .pyx file, as
is standard. To make a Cython implementation, the right packages have to
be imported, just as with numpy. For this specific implementation numpy
had to be imported, and the C version of numpy by doing cimport, the full
code can be seen in listing A.1. In Python there is automatic boundary
checks for loops over arrays and lists, while in C there is not. Python does
also support the use of negative indexes for counting backwards through
the list or array, so that index -1 is the last element and index -2 is the
seconds last element. Cython has implemented support for both these
features, but at the cost of some efficiency. In this implementation these
features are not needed and as a consequence they are turned off. For
Cython to really speed up the code, it needs explicit variable types. It can
handle undeclared variable types as input, but again at a loss of efficiency.
This method takes in four one-dimensional arrays with integers, a start and
a stop array for each track. In Python one does not need to think about what
type of integers the arrays hold, if it is int32 or int64. Cython is typesafe and
hence this can become a problem. The creators of the HyperBrowser have
not been consistent in the use of data types for the arrays, most are int32
and a few are int64. To maintain maximum speed, this made it necessary
to check the datatype of the arrays before sending them into the Cython
method. If the array is int64 it is recast to int32. The overlap method will
return an integer which is the overlap between all segments checked.
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Results
The coming sections about the tool will describe the visuals and include a
step-by-step guide on how to use it. This guide will also be available under
Published Pages on the HyperBrowser. It will also be explained how the
tool presents the results and what information the different elements hold.
In the final section about the tool, the results from the comparison of MS
with B-cells will be presented.
The section about the new algorithm will look at the efficiency of the
algorithm and how it compares to the other options already available in the
HyperBrowser.
5.1 Genomic variation analysis tool
The tool is generated with a graphical user interface to make it easy to use.
The user need not have any programming knowledge as it is all point and
click with the mouse. It uses drop-down lists for selections where the user
can only select one option, and checkboxes for selections when the user
can select more than one option. Submenus, such as normalization type
for enrichment are hidden from user until enrichment is selected. This is
to avoid filling the interface with choices the user does not need to think
about.
It lets the user upload a track with genetic information, and run
different comparisons between it and genetic regions. The regions to
select between are; DHS, TF, H3K4me3 and the chromatin states active
promoter, 4 strong enhancer and 5 strong enhancer. The analyses to choose
between are regions touched, enrichment, hypothesis testing, count points
and average segment length.
5.1.1 Uploading data
The Genomic HyperBrowser supports uploading tracks through the Galaxy
interface it is built upon. The link for that is found underGalaxy Tools, and
is called Get data. For this example the MS confirmed SNPs are stored in
bed format in a plain text file on the computer. The bed file is found in the
tar.gz file on invitro (see section 1.3). The bed format is needed for this tool.
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Figure 5.1: Example of how the tool looks, and how things can be selected.
Left panel are links to different menus, middle panel is the tool, and right
panel contain the history elements. Green history element is finished tasks,
yellow is running tasks, and red is failed tasks.
When hitting theUpload File link a new page is shown, there one selects the
file from local disc and sets file format to bed. The rest is left as it is. When
the execute button is hit, the file is uploaded to the Genomic HyperBrowser
ready to use.
5.1.2 Using the tool
The file is now stored as an element in the history on the right side panel,
and the tool can be selected from themenu on the left side. It is found under
Restricted and experimental tools and is named Analyze TF- or cell type-
specificity of a genomic track. This opens the tool in the middle panel. One
has to select where to get the track from. In this case the track is uploaded
to history, so history is selected. This opens a new drop-down box where
the tracks saved to history can be selected. Select the track wanted.
Now it is time to decide which genetic regions to run this track against.
For this example the chromatin state active promoter has been selected.
But the user can choose more than one if wanted. Each region adds a new
set of subtypes, which in turn increases runtime.
The next choice is to select which analyses to run. For this example
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Figure 5.2: Image of a result page for the GWAS Tool
all the analyses are chosen. Normally that would make the tool run for
some time, but since there are so few subtypes in active promoter, it is fast
enough.
The final step is to select the preferences for the analyses. What box
belongs to what is discussed in section 3.2. The preferences chosen are
observed, regions containing, coverage depth and 0.0005. Figure 5.1 shows
how it should look like after making these selections.
On the right side one can see the history elements. The first one is
uploading theMS confirmed SNPs to the HyperBrowser, it is green because
it finished without errors. The second history element is yellow, which
means it is a task running. It is created when the execute button is clicked,
and it will stay yellow for as long as the calculations take. It will turn red if
something goes wrong, or green if it finishes without errors.
5.1.3 Getting the results
One can click at the eye symbol on the history element to see the results
when it turns green. It will show a table containing the results for all the
subtypes, the table for this run can be seen in fig. 5.2. Under the table, two
graphs will be created. The first shows the enrichment as a bar plot and the
P value on top as a scatter plot. Figure 5.5 is the graph from this run. The
second graph plots the regions touched, and the result is seen in fig. 5.6.
5.1.4 Presenting the results
The table
When the tool is done with the analyses, it generates a web page with the
results. The first things shown are two headers, one saying what track has
been analysed, and the second saying for what region the coming results
are for. This way the information will always be printed in this order, from
top to bottom:
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Figure 5.3: Sub result page for enrichment of MS confirmed in B-cells
Figure 5.4: Sub result page for each chromosome for the enrichment of MS
confirmed in B-cells
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1. Header containing track name
2. Header containing genetic region
3. Table holding all global results
4. Graph based on hypothesis testing and enrichment if calculated,
fig. 5.5
5. Graph based on regions touched if calculated, fig. 5.6
6. If more regions, start over from item 2
The table holds the global results from one genetic region, where the
global results are the results from the entire genome and not just one
chromosome. The first column holds the name of all subtypes, and the
rest of the columns represent a separate analysis, as can be seen in fig. 5.2.
This table has the possibility to sort the results based on each column. By
clicking on the header of a column, that column gets sorted highest number
and down. Click again and the lowest number comes to the top. The table
is created to make it easy for users to find what subtypes to look closer at.
Each number is a link, pointing to a page holding more information
about that analysis. What that page presents will be slightly different
depending on which analysis it is. Figure 5.3 shows the subpage for MS
enrichment in B-cells. If interested one can also get information down to
chromosome level by clicking the values per bin link. Figure 5.4 shows a
part of the table being shown then.
The graphs
There will be up to two graphs presented to the user, depending on what
analyses were selected. Hypothesis testing and enrichment makes for one
graph, while regions touched makes for another. Both of these graphs will
show the 20 subtypes with the best results, or all subtypes if there are less
than 20. The subtypes will be sorted from left to right, low to high.
If hypothesis testing or enrichment has been analysed, there will be a
graph under the table presenting the results. That graph will look slightly
different depending on which of the analyses has been run. It will show the
subtypes with the highest enrichment or lowest p-value. If both have been
run, it will show both enrichment and p-value. This makes it easy to see if
the enrichment may be significant or not. The graph with both p-value and
enrichment can be seen in fig. 5.5. Enrichment is the bars and p-value is
the dots. That is also the case even if one of the analyses have been run.
The second graph will show the subtypes with best results for regions
touched. Figure 5.6 is an example of how it looks, and this will only be
created if regions touched is calculated.
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Figure 5.5: Enrichment of MS confirmed SNPs in active promoters
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Figure 5.6: Regions touched for MS confirme SNPs on active pro oter
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5.1.5 Comparing the results
In “Genomic Regions Associated with Multiple Sclerosis Are Active in B
Cells” [13] it was shown that MS SNPs are enriched in B-cells, and that the
enrichment is higher than what can be expected by chance. When running
MS confirmed in the tool, and comparing it against chromatin states, the
results become the same. Figure 5.2 shows that HmmGm12878HMM, B-
cells, has the highest regions touched and the highest enrichment with 3.5.
The rest of the subtypes have an enrichment between zero and one. B-cells
also have the lowest p-value on hypothesis testing. These three results give
a strong indication that MS variants active in B-cells, which is the same
conclusion as the article came to.
5.2 Genomic track overlap algorithm
When the runtime is kept vague in the following paragraph it is done
intentionally. It is not meant to be highly accurate. The time is measured
on a computer running Red Hat Linux 4. The processor is an Intel(R)
Core(TM) i7 CPU running at 2.93GHz. The time is measured using
t i me.cl ock in Python. Time is kept vague because the needed precautions
have not been taken to be sure the times are accurate. There may be big
time intervals between the runs, and there are almost always some other
programs running in the background that may intervene with how fast the
calculations are done. The time is there just to give an indication on how
fast or slow it runs.
In section 4.2.3 it was explained how the algorithm was improved by
removing one loop and using xr ang e. This increased the speed by huge
amounts. Running nosetests on all the tests is done so fast it is irrelevant
to time it, less than 0.1 seconds to do all the 17 tests. The algorithm was
then tried with the alzheimer with 50kb (alzheimer SNPs with 50000 bases
added to each side) file as trait track, and the merged DHS file as union file.
The runtime became around 0.9 seconds for chromosome five, and around
0.4 seconds for chromosome four before Cython was implemented, giving
the total time across all chromosomes around 11 seconds on the desktop
computer.
5.2.1 Timing in HyperBrowser
The overlap method was then implemented into the HyperBrowser frame-
work to see how it compares there. By using the call graph option in Hy-
perBrowser it is possible to get an idea of how efficient the new algorithm is
and how it scales for bigger sets. The call graph measures the time in CPU
seconds. All of the following tests have been run four times for each algo-
rithm, to increase the chance that the time is accurate. All four times will be
presented, but the focus is on the fastest run as that is what is closest to the
optimal runtime. Ideally one should run more than four tests to be certain
one is close to the optimal time, but the since there is so small differences
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Algorithm Run 1 Run 2 Run 3 Run 4
SumInside 5.951 2.355 2.269 2.415
OverlapNoCython 8.236 8.396 8.072 7.949
OverlapCython 7.405 8.478 7.423 7.382
Table 5.1: Runtime for the different algorithms with MS confirmed with
50kb flanks on DHS regions, measured in CPU seconds
Algorithm Run 1 Run 2 Run 3 Run 4
OnlyT3 29615.027 29628.287 29600.526 29520.023
SumInside 22.653 20.238 19.952 19.855
OverlapNoCython 452.995 463.951 460.234 475.067
OverlapCython 134.379 147.108 146.648 145.897
Table 5.2: Runtime for the different algorithms when doing hypothesis
testing with MS confirmed on DHS regions, measured in CPU seconds
between the runs, one can assume it is close enough and that the conclu-
sion would be the same with more runs. The fastest time for each algorithm
is boldfaced in the tables. SumInside is the one using the coverage track,
OverlapNoCython is the new one without Cython, and OverlapCython is the
new with Cython. The MS confirmed used when testing in HyperBrowser
contains 61 segments or SNPs. While all DHS subtypes is the same as the
union track, with 24046672 segments.
Timing the algorithms
The first tests were to run only the actual algorithms inside the Hyper-
Browser. In table 5.1 the results from running the algorithms on MS con-
firmed SNPs with 50kb flanks is presented. The fastest algorithm is Sum-
Inside, using only 2.268 seconds. SumInside is also the most limiting algo-
rithm, as it does not allow for overlap, and it needs the coverage track.
The two others algorithms end up almost identical in time. Overlap-
NoCython has the slowest time as 7.949 seconds, while OverlapCython is
slightly faster and finishes in 7.382 seconds. To understand why these two
end up being so identical in time, one must go into the call graph and look
at time spent in each method. Then one can see that on the fastest run,
the actual counting of overlap took 8.42% (0.67 seconds) of the total time.
While with OverlapCython it is so fast that the call graph does not present
it. But since OverlapCython is type dependent, the method calling the over-
lap algorithms has to check and maybe recast the types. That increases the
time spent in that method from 0.11% to 0.15%. This also shows that the al-
gorithms are reasonably fast, and that the bottleneck probably is something
else.
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Algorithm Run 1 Run 2 Run 3 Run 4
OnlyT3 37746.745 37826.370 37811.998 37910.405
SumInside 2703.704 2719.715 2708.498 2697.290
OverlapNoCython 1861.890 1920.645 1823.519 1843.009
OverlapCython 172.671 173.990 183.637 174.551
Table 5.3: Runtime for the different algorithms when doing hypothesis
testing with CD19 on DHS regions, measured in CPU seconds
Timing it on hypothesis testing
Next it is interesting to see how the algorithms perform in an actual anal-
ysis. Hypothesis testing with MS confirmed SNPs on 325 - GM12878 (a
subtype of DHS), normalized based on coverage depth. For this, there are
four algorithms that can be used to find the overlap, SumInside, Overlap-
NoCython, OverlapCython and OnlyT3. OnlyT3 is the old algorithm that
allowed overlapping segments, and it is used if no coverage depth track ex-
ists. There were 50 randomized tries done for this test. The results can be
seen in table 5.2. It is clear that the slowest algorithm is OnlyT3 as it used
29520.023 seconds (more than 8 hours). SumInside was by far the fastest
one, using only 19.855 seconds. OverlapNoCython used 452.995 seconds
(about 7 minutes) and OverlapCython used 134.379 seconds (about 2 min-
utes). Again it might be interesting to take a look at how much time is used
on actually calculating the overlap. For OverlapNoCython it uses 70.11%
(about 5 minutes) of the time calculating the overlap, while OverlapCython
uses 3.91% (about 5 seconds). A part of the call graph for OverlapCython
can be seen in fig. A.1a
Timing it on hypothesis testing, bigger set
To see how this scaled when the trait track becomes big, the same tests
were run as in section 5.2.1. But this time it was tried with CD19 as trait
track, and checked against 1 - A549. Both of these are subtypes of DHS,
which probably makes it biologically uninteresting to do a test like this.
But the size of CD-19 makes it algorithmically interesting. CD-19 contains
75086 segments, and is thus much larger than theMS track. The results are
presented in table 5.3. OnlyT3 is again the slowest one, using 37746.745
seconds (more than 10 hours). SumInside is now the second slowest
using 2697.290 seconds (almost 45 minutes), the OverlapNoCython uses
1823.519 secods (almost 31 minutes). And OverlapCython used 172.671
seconds (almost 3 minutes). By taking a closer look at the two algorithms
again, one can see that 91.16% (almost 28 minutes) of the time is used to
count the overlap in OverlapNoCython. While with OverlapCython it uses
only 7.38% (almost 13 seconds) to count the overlap. A part of the call graph
for OverlapCython can be seen in fig. A.1b.
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Discussion
This chapter will consist of three parts. The first part covers how to interact
with the HyperBrowser and how to save time when working with it. The
next section will cover weaknesses in the tool and the overlap algorithm;
why they exist, and what can be done with them. Future work will be
discussed in the final section; what more can be done, and what should
be done before it is released as a finished tool.
6.1 Legacy Code
In this section some guidelines for adding new functionality to the
HyperBrowser will be explained, the examples should work for adding
functionality to legacy code in general as well. The guidelines are created
based on mistakes made and experience learned while working with the
HyperBrowser. Many mistakes and much time could have been saved
if these guidelines had been followed when creating the tool. The new
functionality can be one or more methods added to the HyperBrowser,
without the need to really change existing code.
6.1.1 Collect the right information
The first task after deciding what function to add, should be to collect in-
formation. Consider the following questions: Where in the HyperBrowser
should it be added? What methods does the new function need to call?
What do the methods return? It is also useful to look at what other func-
tions use these methods, this way it is possible to collect information about
what comes in and what goes out of those methods. Wrap the methods in
print statements, print everything going in, everything going out and also
put print statements inside the methods if possible. Then run the functions
using these methods, but run them on small cases. The faster a test can
finish, the better. If it takes a day to write a smaller test case that takes a
few minutes run, when the original case takes a few hours, then it does not
take many runs to make it worth it. Eventually the code will start to make
more sense, and it will be clearer what all the variables are. Then the time
has come to look for testing points.
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6.1.2 Finding the points and writing the tests
The first and most obvious place to write tests, are for the variables being
returned by the methods already in the HyperBrowser. This makes it clear
what variables the new function has to work with from the HyperBrowser
code. More generally any part of the new function that interacts with
HyperBrowser code should be tested. Any variables going from the new
function to the HyperBrowser should be checked, and the variables being
returned to the new function should be checked. The tests for variables
being sent from the HyperBrowser to the new functionality can be run
before the actual functionality is in place, as they should be able to pass.
When those are done, it is time to write the tests for the new functionality,
it should by now be clear what it should pass to other methods and what it
should get back. These tests will, of course, be failing until the methods in
the new functionality gets written.
When all the tests are running, then the new functionality should be
running properly for at least the cases tested. It may then be useful to make
sure that all possible cases are actually covered by a test case.
6.1.3 Make sure examples are correct
If the new functionality is to make use of information, paths, program
examples or similar, then make sure they are correct. If the new
functionality is supposed be a graphical interface for some analyses
run with batchlines, then make sure the batchlines are working before
implementing them. It is easier to debug if the batchlines are run through
the Debug batchlinesmethod in the HyperBrowser, compared to if it is run
through another tool. Wait to implement them until they actually run as
they should.
6.2 Weaknesses
The following subsections will look at different weaknesses in both the tool
and the new overlap algorithm. The weaknesses will be explained, and
possible solutions will be presented.
6.2.1 Genomic variation analysis tool
Lack of explanations
One of the first weaknesses one might find is that the tool contains very few
explanations. Each selection only contains a name or a short statement.
This can make the tool difficult to understand for a user with little or no
knowledge about the HyperBrowser, the genetic regions or the analyses. If
the user wants to load a track from history, but has no bed tracks in history,
then the drop-down list comes up empty without any explanations.
The tool assumes that the user knows what the different genetic regions
are; it does not, for example, explain what DHS is or when that is a good
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choice. As to the analyses, these to have no explanations. It is assumed that
the user knows the difference between enrichment and hypothesis testing,
or what regions the average segment length is calculated for.
The reason why no explanation or extra information has been added, is
simply because it has not been a priority. The tool is a proof of concept, and
thus it will not be released out to many users with no knowledge of this.
Lack of error handling
The tool does no testing to make sure that the users use it correctly. The
tool will try to run if the user hits execute without selecting a track, and the
history element will turn red due to a crash. Nothing will show up if the link
to the results is selected, and the message showing where Python crashed
will show if the history element is expanded and the bug is clicked. If a trait
track is selected but no genetic regions and no analysis, it will run and turn
green. However, there will be no results showing, and no message to the
user about why there are no results. If an analysis is selected without any
genetic region, the same will happen. Again, if a genetic region is selected,
but no analysis, the same will happen as if no track was selected. There
is also no checking to make sure that the trait track actually is of the right
type. If the user tries to use a trait track with genetic information that is not
made for the hg19/GRCh37, the results may be wrong or it might even fail
if the information is outside the correct genetic regions.
Once again, this is not implemented, due to this being a proof of
concept, which has made that less of a prioritized task.
The code is not flexible enough
Although it is reasonable easy to add new genetic regions to the objects,
it is not easy enough to modify the code in general. The code could have
been made more flexible, making it easier to expand with new analyses and
genetic regions, especially the code for the tool.
Since the user does not see the code of this tool, this has not been the
focus. As a proof of concept, it is not important to have perfect code. The
user does not see this anyway.
Could have been parallelized
This tool is currently doing everything linear, it does many time consuming
independent steps after each other. Since these steps are more or less
completely independent, this could be parallelized. Each genetic region
could be done in a separate process, then each process would get its own
instance of a region object and the path to the trait track. This would
probably greatly increase the efficiency, as some of these genetic regions
can take many hours to finish if enough analyses is selected.
This has not been implemented for two reasons, firstly the Hyper-
Browser has a feature for automatic parallelization (currently turned). This
means that the work ofmaking the code parallel might become redundant if
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the feature is activated again. Secondly, this tool is made to show scientists
what can be done; how easy it could be made to do these types of analyses,
and parallelization does not improve that.
6.2.2 Genomic track overlap algorithm
Efficiency
The two new algorithms performed equally well when running on MS con-
firmed with 50kb flanks against DHS. SumInside on the other hand per-
formed much better. This result is interesting, since the OverlapNoCython
only used slightly more than half a second in the actual overlap algorithm.
And OverlapCython used so little time that it did not even show on the call
graph.
The differences become much clearer when using the algorithms on an
actual hypothesis test. SumInside is still the fastest for small trait tracks,
but when the trait track gets big that changes. MS confirmed contains 61
segments, while CD-19 contains 75086 segments. This means that the
number of segments in the trait track was increased almost 1231 fold.
For the SumInside the time then increased by 135 fold, while with the
OverlapCython it increased only 1.3 fold. These numbers, combined with
the call graph showing that 73.1% of the time was spent collecting arrays
in the OverlapCython, might mean that to increase efficiency one might
benefit more from looking at how the data is collected or the HyperBrowser
in general, than at the actual algorithm.
Strict data type
One might think that one weakness of the algorithm is that it is typesafe,
and it will be, if the integers start to get bigger than 2147483647 (maximum
number for int32) or if they start using int64 as standard. It is a simple task
to modify the Cython code to accept int64, or any other type. The small test
done to check the type of the arrays, and recasting them if necessary, is
also easy to change. The test is written so that only one variable has to be
modified to fit the new data type. Since the numbers represent points along
the natural line, there is no reason they should change to floats. It would
only be a small change in the Cython code and a recompiling of the code,
if they chould decide to change the array type. This means that the extra
work that might come from Cython being typesafe, is easily beaten by its
efficiency.
6.3 Future work
6.3.1 Genomic variation analysis tool
Before too much is changed with the tool, there should be added somemore
explanations to the tool. So as to make it clear what each selection does.
Then it should be introduced to a selected group of scientists. That way
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more feedback could be collected, and it would be easier to know how to
further design the tool to their needs. One scientist has already tried the
tool, and his wishes for further work are more information about which
regions are affecting the enrichment value, more information about what
the actual analyses does and more regions added to the chromatin states.
There are several things that can be done as further work for this
tool. The structure between the tool in the HyperBrowser and the
GwasBatchLines class should probably be changed. It is fairly simple to
add another genetic region, but it is somewhat more difficult to add a
new analysis, but both of these should be improved. This would make the
tool more flexible, and easier to modify as the need of the scientists might
change with new discoveries.
Depending on what is decided in regards to the parallelization feature,
it might be relevant to increase efficiency by parallelizing the code. There is
no doubt that it would make the code faster, but it would have to take into
account for limited system resources.
6.3.2 Genomic track overlap algorithm
There are mainly two things that can be done as further work. The first is
to expand the algorithm, or make a new one, allowing for internal overlap
in both tracks. This should probably be done as a new algorithm, as it will
affect the efficiency of the algorithm.
The second thing that could be done, is to look at how theHyperBrowser
stores and collects the data. Since collecting the data is what takes the most
time with the current algorithm.
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Conclusion
The main goal was to develop a proof of concept for an easy to use tool for
analysing GWAS data, typically genetic variations. Using this tool the user
can upload a track containing information about these variations, and then
analyse it against certain genomic regions, looking for cell type specificity.
The results were to be presented so that it is easy to find the results of
interest.
This tool was created in the Genomic HyperBrowser, with a graphical
interface for ease of use. The tool has been tried by one scientist, and the
feedback was positive. He is satisfied with how easy the tool is to use. The
tool is publicly available at http://hyperbrowser.uio.no/personal/.
A subgoal became to improve efficiency of the more flexible algorithm,
so that the tool easier could be expanded to do analyses on different regions.
Amore efficient algorithmwas developed that allows for internal overlap in
one of the tracks. It also becomes much faster than the stricter algorithm
when the track without overlap becomes large.
In conclusion, the tool became flexible and easy to use, and the
algorithm greatly decreased the time it takes to find the overlap between
two tracks where one has internal overlapping segments.
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1 import numpy as np
2 cimport numpy as np
3 cimport cython
4 from cpython cimport bool
5 ctypedef np.int64 DT
6
7 @cython.boundscheck(False) # turn o f f array bounds check
8 @cython.wraparound(False) # turn o f f negat ive ind ice s (u[−1 ,−1])
9 cpdef overlapCython(np.ndarray[DT, ndim=1] traitStart,
10 np.ndarray[DT, ndim=1] traitStop,
11 np.ndarray[DT, ndim=1] unionStart,
12 np.ndarray[DT, ndim=1] unionStop) :
13 cdef int traitLen, unionLen
14 cdef int tmpInd, i , k,
15 cdef int count, start, stop
16 cdef bool flag
17 traitLen = traitStart.size
18 unionLen = unionStart.size
19
20 count = 0
21 tmpInd = 0
22 fo r i in xrange(traitLen) :
23 start = traitStart[i]
24 stop = traitStop[i]
25 indStart = tmpInd
26 flag = True
27 fo r k in xrange(indStart, unionLen) :
28 i f start >= unionStop[k] and flag:
29 tmpInd = k+1
30 e l i f start >= unionStart[k] and start < unionStop[k] :
31 # i f t r a i t s t a r t ins ide union sequence
32 flag = False
33 i f stop <= unionStop[k ] :
34 count += stop−start
35 e l s e :
36 count += unionStop[k]−start
37 e l i f stop > unionStart[k] and stop <= unionStop[k] :
38 flag = False
39 i f start <= unionStart[k] :
40 count += stop − unionStart[k]
41 e l i f unionStart[k] >= start and unionStop[k] <= stop:
42 flag = False
43 count += unionStop[k] − unionStart[k]
44 e l i f stop <= unionStart[k] :
45 flag = False
46 break
47 return count
Listing A.1: Cython code of the overlap method before compilation
79
APPENDIX A. CYTHON
1 from distutils.core import setup
2 from distutils.extension import Extension
3 import numpy as np
4 from Cython.Distutils import build_ext
5
6 cymodule = ' overlapCython ' # Name of cython f i l e
7 setup(
8 name=cymodule
9 ext_modules=[
10 Extension(cymodule, [cymodule + ' . pyx ' ] ,
11 include_dirs=[np.get_include( ) ] ) ] ,
12 cmdclass={ ' bui ld_ext ' : build_ext} ,
13 )
Listing A.2: Setup file compiling Cython code
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